

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
 NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
 NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
 NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
 NEWS 8 JAN 29 PHAR reloaded with new search and display fields
 NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
 NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
 NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
 NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13 FEB 26 MEDLINE reloaded with enhancements
 NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
 NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
 NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19 MAR 16 CASREACT coverage extended
 NEWS 20 MAR 20 MARPAT now updated daily
 NEWS 21 MAR 22 LWPI reloaded
 NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
 NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
 NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
 NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
 NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
 NEWS 28 MAY 01 New CAS web site launched
 NEWS 29 MAY 08 CA/CAPLUS Indian patent publication number format defined
 NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
 NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data
 NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload
 NEWS 33 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
 NEWS 34 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
 NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007

=> file reg
 COST IN U.S. DOLLARS

SINCE FILE TOTAL
 ENTRY SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2
DICTIONARY FILE UPDATES: 7 JUN 2007 HIGHEST RN 936802-99-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e vitamin.b1/cn

E1	1	VITAMIN B, PHOSPHATE (1:2) (SALT)/CN
E2	1	VITAMIN B-VITAMIN C MIXTURE/CN
E3	1	--> VITAMIN B1/CN
E4	1	VITAMIN B1 DIPHOSPHATE SALT/CN
E5	1	VITAMIN B1 DISULFIDE/CN
E6	1	VITAMIN B1 HYDROCHLORIDE/CN
E7	1	VITAMIN B1 LAURYL SULFATE/CN
E8	1	VITAMIN B1 MONONITRATE/CN
E9	1	VITAMIN B1 MONOPHOSPHATE/CN
E10	1	VITAMIN B1 MONOPHOSPHATE CHLORIDE/CN
E11	1	VITAMIN B1 MONOPHOSPHATE SALT/CN
E12	1	VITAMIN B1 NITRATE/CN

=> s e3

L1 1 "VITAMIN B1"/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 59-43-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-
4-methyl- chloride (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Thiamine (8CI)

CN Thiazolium, 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-
4-methyl- chloride (9CI)

OTHER NAMES:

CN 3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-
methylthiazolium chloride

CN Aneurine

CN Apatate Drape

CN Beivon

CN Bethiamin

CN Oryzanin

CN Thiacoat

CN Thiamin

CN Thiamine monochloride

CN Vitamin B1

CN Vitaneurin

DR 57777-32-9, 55463-15-5, 115461-66-0, 100660-17-1

MF C12 H17 N4 O S . Cl

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,


CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSChem, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

CRN (70-16-6)



Cl⁻

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23452 REFERENCES IN FILE CA (1907 TO DATE)

348 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

23521 REFERENCES IN FILE CAPLUS (1907 TO DATE)

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> e pioglitazone/cn

E1	1	PIOESTER 4248, POLYMER WITH 1,3,5-TRIS(OXIRANYLMETHYL)-1,3,5-TRIAZINE-2,4,6(1H,3H,5H)-TRIONE/CN
E2	1	PIOESTER 4350-55/CN
E3	1	--> PIOGLITAZONE/CN
E4	1	PIOGLITAZONE 2-IMINE/CN
E5	1	PIOGLITAZONE HYDROCHLORIDE/CN
E6	1	PIOGLITAZONE N-OXIDE/CN
E7	1	PIOGLITAZONE NITRATE/CN
E8	1	PIOKTANIN/CN
E9	1	PIOLENE 1802/CN
E10	1	PIOLOFORM BL 16/CN
E11	1	PIOLOFORM BL 18/CN
E12	1	PIOLOFORM BL 24/CN

=> s e3

L2 1 PIOGLITAZONE/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 111025-46-8 REGISTRY

ED Entered STN: 31 Oct 1987

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(±)-

OTHER NAMES:

CN 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione

CN **Pioglitazone**

CN U 72107

CN Zactos

DR 105355-27-9, 198077-89-3

MF C19 H20 N2 O3 S


CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSChem, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,

SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO

PAGE 1-A



PAGE 2-A

Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1588 REFERENCES IN FILE CA (1907 TO DATE)
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1607 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e rosiglitazone/cn

E1	1	ROSIFOLIOL/CN
E2	1	ROSIGENIN/CN
E3	1 -->	ROSIGLITAZONE/CN
E4	1	ROSIGLITAZONE MALEATE/CN
E5	1	ROSIGLITAZONE MALEATE HYDRATE/CN
E6	1	ROSIGLITAZONE NITRATE/CN
E7	1	ROSIGLITAZONE SODIUM/CN
E8	1	ROSIGLIZOLE/CN
E9	1	ROSIL/CN
E10	1	ROSIL 10/CN
E11	1	ROSIL 175/CN
E12	1	ROSIL C18/CN

=> s e3

L3 1 ROSIGLITAZONE/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 122320-73-4 REGISTRY

ED Entered STN: 25 Aug 1989

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (CA INDEX NAME)


OTHER NAMES:

CN 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione


CN 5-[[4-[2-[N-Methyl-N-(2-pyridyl)amino]ethoxy]phenyl]methyl]thiazolidine-

2,4-dione
 CN BRL 49653
 CN **Rosiglitazone**
 CN Rosiglitazone
 CN TDZ 01
 MF C18 H19 N3 O3 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
 IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC,
 PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER,
 USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1975 REFERENCES IN FILE CA (1907 TO DATE)
 16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2005 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e cs-011/cn

E1	1	CS ULTRAFILTER/CN
E2	1	CS (LACRIMITOR)/CN
E3	0 -->	CS-011/CN
E4	1	CS-1/CN
E5	2	CS-116M/CN
E6	1	CS-1170 DICYCLOHEXYLAMINE SALT/CN
E7	1	CS-1170 SODIUM SALT/CN
E8	2	CS-117M/CN
E9	2	CS-118M/CN
E10	2	CS-119M/CN
E11	2	CS-120M/CN
E12	1	CS-121M/CN

=> e cs 011/cn

E1	1	CS 003/CN
E2	1	CS 01-183F14C/CN
E3	1 -->	CS 011/CN
E4	1	CS 01300110/CN
E5	1	CS 0130080/CN
E6	1	CS 0130090/CN
E7	1	CS 015/CN
E8	1	CS 018/CN
E9	1	CS 02/CN
E10	2	CS 023/CN
E11	1	CS 027/CN
E12	1	CS 038/CN

=> s e3

L4 1 "CS 011"/CN

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 524675-01-2 REGISTRY
ED Entered STN: 03 Jun 2003
CN CS 011 (CA INDEX NAME)
ENTE A new-generation glitazone for the treatment of type 2 diabetes (Sankyo)
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

STRUCTURE DIAGRAM IS NOT AVAILABLE

9 REFERENCES IN FILE CA (1907 TO DATE)

9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e tak 559/cn

E1	1	TAK 475/CN
E2	1	TAK 536/CN
E3	1 -->	TAK 559/CN
E4	1	TAK 599/CN
E5	1	TAK 60/40/CN
E6	1	TAK 603/CN
E7	1	TAK 637/CN
E8	1	TAK 652/CN
E9	1	TAK 661/CN
E10	1	TAK 677/CN
E11	1	TAK 70/CN
E12	1	TAK 70-85/CN


=> s e3

L5 1 "TAK 559"/CN

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 250601-04-8 REGISTRY
ED Entered STN: 10 Dec 1999
CN Benzenebutanoic acid, γ -[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γ E)- (CA INDEX NAME)
OTHER NAMES:
CN Imiglitazar
CN **TAK 559**
FS STEREOSEARCH
MF C28 H26 N2 O5
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e fk 614/cn

E1	1	FK 6120/CN
E2	1	FK 613/CN
E3	1 -->	FK 614/CN
E4	1	FK 615/CN
E5	1	FK 633/CN
E6	1	FK 64/CN
E7	1	FK 66/CN
E8	1	FK 664/CN
E9	1	FK 68/CN
E10	1	FK 687/CN
E11	1	FK 7/CN
E12	1	FK 700/CN

=> s e3

L6 1 "FK 614"/CN

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 193012-35-0 REGISTRY

ED Entered STN: 22 Aug 1997

CN 1H-Benzimidazole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (CA INDEX NAME)

OTHER NAMES:

CN 1-(2,4-Dichlorobenzyl)-2-Methyl-6-(1-Pentanesulfonylcarbamoyl)Benzimidazole


CN **FK 614**

DR 400608-02-8

MF C21 H23 Cl2 N3 O3 S

SR CA

LC STN Files: CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

23 REFERENCES IN FILE CA (1907 TO DATE)
23 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

L1 E VITAMIN B1/CN
1 S E3
L2 E PIOGLITAZONE/CN
1 S E3
E ROSIGLITAZONE/CN
L3 1 S E3
E CS-011/CN
E CS 011/CN
L4 1 S E3
E TAK 559/CN
L5 1 S E3
E FK 614/CN
L6 1 S E3

=> file merck

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
47.70	47.91

FULL ESTIMATED COST

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

COPYRIGHT (C) 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserve

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005


THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

=> s l1

L7 1 L1


=> d all

L7 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
Whitehouse Station, New Jersey, USA. All rights reserved. on STN
MERCK Number (MNO): 9366
CAS Registry No. (RN): 59-43-8
MERCK Index Name (MIN): Thiamine
CA Index Name (CN): 3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
Synonym(s) (CN): Vitamin B1; Aneurin; Thiamine monochloride; Thiaminium chloride
Molecular Form. (MF): C12 H17 Cl N4 O S
Wgt Composition (COMP): C 47.91%, H 5.70%, Cl 11.79%, N 18.63%, O 5.32%, S 10.66%.
Molecular Weight (MW): 300.81
References (RE): Essential nutrient required for carbohydrate metabolism; also involved in nerve function. Biosynthesized by microorganisms and plants. Dietary sources include whole grains, meat products, vegetables, milk, legumes and fruit. Also present in rice husks and yeast. Converted in vivo to thiamine diphosphate, a coenzyme in the decarboxylation of α -keto acids. Chronic deficiency may lead to neurological impairment, beriberi, Wernicke-Korsakoff syndrome. Isolated from rice bran: B. C. P. Jansen, W. F. Donath, Chem. Weekbl. 23, 201 (1926). Structure: R. R. Williams, J. Am. Chem. Soc. 58, 1063 (1936); R. R. Williams, J. K. Cline, ibid. 1504; R. R. Williams et al., ibid. 59, 526 (1937). Review of syntheses: Knobloch in H. Vogel, Chemie und Technik der Vitamine vol. II (Stuttgart, 1953) pp 1-128. Toxicity data: D. Winter et al., Int. Z. Vitaminforsch. 37, 82 (1967). HPLC determined in foods, pharmaceuticals, body tissues: T. Kawaski, Methods Enzymol. 122, 15 (1986); in plasma and pharmacokinetics: H. Mascher, C. Kikuta, J. Pharm. Sci. 82, 56 (1993). Review of bioavailability, absorption, and role in nutrition: F. L. Iber et al., Am. J. Clin. Nutr. 36, 1067-1082 (1982). Reviews: "Thiamin-Twenty Years of Progress", Ann. N.Y. Acad. Sci. 378, H. Z. Sable, C. J. Grubier, Eds. (1982) 470 pp; "Thiamin, Vitamin B1, Aneurin" in Vitamins, W. Friedrich, Ed. (de Gruyter, Berlin, 1988) pp 339-401.



Cl⁻

== DERIVATIVE == (1): Hydrochloride
 CAS Registry No. (RN.DRV): 67-03-8
 Synonym(s) (CN.DRV): Thiamine chloride hydrochloride; Thiamine dichloride
 Trade Name(s) (CN.DRV): Benerva (Roche); Betabion (Merck KGaA); Betalin S (Lilly); Betaxin (Sterling-Winthrop); Bewon (Wyeth); Metabolin (Takeda); Vitaneurin (Mepha)
 Molecular Form. (MF.DRV): C₁₂ H₁₇ Cl N₄ O S . Cl H
 Wgt Composition (COMP.DRV): C 42.73%, H 5.38%, Cl 21.02%, N 16.61%, O 4.74%, S 9.51%.
 Molecular Weight (MW.DRV): 337.27
 References (RE.DRV): Comprehensive description: K. A. M. Al-Rashood et al., Anal. Profiles Drug Subs. 18, 413-458 (1989).




Cl⁻


HCl

Toxicity (TOX.DRV):
 LD50 in mice (mg/kg): 89.2 i.v.; 8224 orally (Winter).
 Other Properties (OCPP.DRV):
 Monoclinic plates in rosette-like clusters. Slight thiazole odor. Bitter taste. dec 248°. One gram dissolves in ~1 ml water, 18 ml glycerol, 100 ml 95% alcohol, 315 ml abs alcohol; more sol in methanol. Sol in propylene glycol. Practically insol in ether, benzene, hexane, chloroform. pH of a 1% w/v soln in water 3.13; pH of a 0.1% w/v soln in water 3.58. On exposure to air of average humidity, the vitamin absorbs an amount of water corresponding to nearly one mol, forming a hydrate.
 LD50 in mice (mg/kg): 89.2 i.v. ; 8224 orally (Winter) .

== DERIVATIVE == (2): Mononitrate
 CAS Registry No. (RN.DRV): 532-43-4
 Molecular Form. (MF.DRV): C₁₂ H₁₇ N₅ O₄ S
 Wgt Composition (COMP.DRV): C 44.03%, H 5.23%, N 21.39%, O 19.55%, S 9.80%.
 Molecular Weight (MW.DRV): 327.36
 References (RE.DRV): Prepn: R. J. Turner, G. J. Schmitt, US 2844579 (1958 to Am. Cyanamid).

CM 1





Melting Point (MP.DRV):

Deriv. Number	Derivative Type	Value MP.DRV deg C	Note
2	Mononitrate	196 - 200	(dec)

Other Properties (OCPP.DRV):

Crystals, mp 196-200° (dec). Practically nonhygroscopic. pKa 4.8. Soly in water (g/100 ml): 2.7 (25°); ~30 (100°). pH of 2% aq soln 6.5 to 7.1. More stable than the hydrochloride; suitable for enrichment of flours and feeds, multivitamin preps.

Therapeutic Codes (THER):

Vitamin (enzyme cofactor).

Therapeutic Codes (Veterinary) (VTHER):

Vitamin (enzyme cofactor).

Referenced Patent (RPN):


US2844579

=> s l2

L8 1 L2

=> d all

L8 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
Whitehouse Station, New Jersey, USA. All rights reserved. on STN
MERCK Number (MNO): 7533
CAS Registry No. (RN): 111025-46-8
MERCK Index Name (MIN): Pioglitazone
CA Index Name (CN): 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
Synonym(s) (CN): (±)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
Drug Code(s) (CN): AD-4833
Molecular Form. (MF): C19 H20 N2 O3 S
Wgt Composition (COMP): C 64.02%, H 5.66%, N 7.86%, O 13.47%, S 9.00%.
Molecular Weight (MW): 356.44
References (RE): Insulin sensitizer. Prepn: K. Meguro, T. Fujita, EP 193256; eidem, US 4687777 (1986, 1987 both to Takeda); T. Sohda et al., Arzneim.-Forsch. 40, 37 (1990). Pharmacology: H. Ikeda et al., ibid. 156. HPLC determ in serum: W. Z. Zhong, D. B. Lakings, J. Chromatogr. 490, 377 (1989). Mechanism of action: C. Hofmann et al., Endocrinology 129, 1915 (1991); M. Kobayashi et al., Diabetes 41, 476 (1992). Effect on adipocyte differentiation: T. Sandouk et al., Am. J. Physiol. 264, C1600 (1993). Clinical evaluation in noninsulin-dependent diabetes: R. Kawamori et al., Diabetes Res. Clin. Pract. 41, 35 (1998).



Et

Melting Point (MP):


Value
MP
deg C
=====

183 - 184

Other Properties (OCPP):

Colorless needles from DMF + water, mp 183-184° .

== DERIVATIVE == (1): Hydrochloride
CAS Registry No. (RN.DRV): 112529-15-4
Drug Code(s) (CN.DRV): U-72107A
Trade Name(s) (CN.DRV): Actos (Takeda)
Molecular Form. (MF.DRV): C19 H20 N2 O3 S . Cl H
Wgt Composition (COMP.DRV): C 58.08%, H 5.39%, N 7.13%, O 12.22%, S 8.16%, Cl 9.02%.
Molecular Weight (MW.DRV): 392.90



HCl

Melting Point (MP.DRV):

Deriv. | Derivative | Value

Number	Type	MP.DRV deg C
1	Hydrochloride	193 - 194

Other Properties (OCPD.DRV):

Colorless prisms from ethanol, mp 193-194°. Sol in DMF; slightly sol in ethanol; very slightly sol in acetone, acetonitrile. Practically insol in water; insol in ether.

Therapeutic Codes (THER):

Antidiabetic.

Referenced Patent (RPN):

EP193256; US4687777

=> s 13

L9 1 L3

=> d all

L9 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
Whitehouse Station, New Jersey, USA. All rights reserved. on STN

MERCK Number (MNO): 8346

CAS Registry No. (RN): 122320-73-4

MERCK Index Name (MIN): Rosiglitazone

CA Index Name (CN): 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-
2,4-thiazolidinedione

Synonym(s) (CN): 5-[4-[2-[N-methyl-N-(2-pyridinyl)amino]ethoxy]benzyl]-
2,4-thiazolidinedione

Drug Code(s) (CN): BRL-49653


Molecular Form. (MF): C18 H19 N3 O3 S


Wgt Composition (COMP): C 60.49%, H 5.36%, N 11.76%, O 13.43%, S 8.97%.

Molecular Weight (MW): 357.43

References (RE): Insulin sensitizer; binds to peroxisome proliferator
activated receptor gamma (PPAR-γ). Prepn: R. M. Hindley, EP
306228; idem, US 5002953 (1989, 1991 both to Beecham); B. C. C. Cantello
et al., J. Med. Chem. 37, 3977 (1994). Pharmacology: N. D. Oakes et al.,
Diabetes 43, 1203 (1994). Binding study: D. E. Mais et al., Med. Chem.
Res. 7, 325 (1997). Clinical pharmacokinetics and bioavailability: M. I.
Freed et al., Eur. J. Clin. Pharmacol. 55, 53 (1999). Review of
pharmacology and clinical experience: J. A. Barman Balfour, G. L.
Plosker, Drugs 57, 921-930 (1999).

PAGE 1-A





Melting Point (MP):

Value
MP
deg C
=====



153 - 155

Other Properties (OCPP):


Colorless crystals from methanol, mp 153-155° .

== DERIVATIVE == (1): Maleate
CAS Registry No. (RN.DRV): 155141-29-0
Drug Code(s) (CN.DRV): BRL-49653c
Trade Name(s) (CN.DRV): Avandia (GlaxoSmithKline)
Molecular Form. (MF.DRV): C18 H19 N3 O3 S . C4 H4 O4
Wgt Composition (COMP.DRV): C 55.80%, H 4.90%, N 8.87%, O 23.65%, S 6.77%.
Molecular Weight (MW.DRV): 473.50

CM 1



Double bond geometry as shown.



Melting Point (MP.DRV):

Deriv. Number	Derivative Type	Value MP.DRV deg C
1	Maleate	122 - 123

Other Properties (OCPD.DRV):

White to off-white solid, mp 122-123° . pKa 6.1; 6.8. Readily sol in ethanol and in buffered aq soln with pH of 2.3; soly decreases with increasing pH in the physiological range.

Therapeutic Codes (THER):

Antidiabetic.

Referenced Patent (RPN):

EP306228; US5002953

=> s 14

L10 0 L4

=> s 15

L11 0 L5

=> s 16

L12 0 L6

=> file medline\

'MEDLINE\' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'MRCK'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=>

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'MRCK' AT 19:20:18 ON 08 JUN 2007

FILE 'MRCK' ENTERED AT 19:20:18 ON 08 JUN 2007

COPYRIGHT (C) 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserve

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

10.03 57.94

=> file medline

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

10.03 57.94

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

FILE LAST UPDATED: 8 Jun 2007 (20070608/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L13 7457 L1

```

=> s (vitamin b1 or thiamine or thiamin)
    136901 VITAMIN
    19853 B1
    2116 VITAMIN B1
        (VITAMIN(W)B1)
    11776 THIAMINE
    1962 THIAMIN
L14    12991 (VITAMIN B1 OR THIAMINE OR THIAMIN)

=> s l13 or l14
L15    13000 L13 OR L14

=> s l2
L16    1041 L2

=> s pioglitazone
L17    1426 PIOGLITAZONE

=> s l16 or l17
L18    1426 L16 OR L17

=> s l3
L19    1361 L3

=> s rosiglitazone
L20    1891 ROSIGLITAZONE

=> s l19 or l20
L21    1891 L19 OR L20

=> s cs-011
    140624 CS
    7409 011
L22    0 CS-011
        (CS(W)011)

=> s (tak-559 or fk-614)
    1253 TAK
    3228 559
    4 TAK-559
        (TAK(W)559)
    3041 FK
    2434 614
    1 FK-614
        (FK(W)614)
L23    5 (TAK-559 OR FK-614)

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007
    E VITAMIN B1/CN
L1      1 S E3
    E PIOGLITAZONE/CN
L2      1 S E3
    E ROSIGLITAZONE/CN
L3      1 S E3
    E CS-011/CN
    E CS 011/CN
L4      1 S E3
    E TAK 559/CN
L5      1 S E3
    E FK 614/CN
L6      1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007
L7      1 S L1
L8      1 S L2
L9      1 S L3
L10     0 S L4
L11     0 S L5

```

```

L12          0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007
L13          7457 S L1
L14          12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15          13000 S L13 OR L14
L16          1041 S L2
L17          1426 S PIOGLITAZONE
L18          1426 S L16 OR L17
L19          1361 S L3
L20          1891 S ROSIGLITAZONE
L21          1891 S L19 OR L20
L22          0 S CS-011
L23          5 S (TAK-559 OR FK-614)

=> s l15 and l18
L24          0 L15 AND L18

=> s l14 and l21
L25          0 L14 AND L21

=> s l14 and l23
L26          0 L14 AND L23

=> s diabet?
L27          286036 DIABET?

=> s l15 and l21
L28          0 L15 AND L21

=> s l15 and l27
L29          317 L15 AND L27

=> d 300-317

L29 ANSWER 300 OF 317      MEDLINE on STN
Full Text
AN 52087354      MEDLINE
DN PubMed ID: 14957244
TI Diabetes mellitus.
AU BEASER S B
SO The New England journal of medicine, (1952 Sep 11) Vol. 247, No. 11, pp.
397-403; concl.
Journal code: 0255562. ISSN: 0028-4793.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5222-43703-109-134
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 301 OF 317      MEDLINE on STN
Full Text
AN 52064859      MEDLINE
DN PubMed ID: 14934749
TI Pyruvate content of blood and phosphorylation of thiamine in diabetic
coma.
AU LICHTENBELT H VAN M; FLORIJN E
SO Biochimica et biophysica acta, (1952 Mar) Vol. 8, No. 3, pp. 349-50.
Journal code: 0217513. ISSN: 0006-3002.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5222-20887-134-387-496
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 302 OF 317      MEDLINE on STN

```


Full Text

AN 52062898 MEDLINE
DN PubMed ID: 14932788
TI The action of insulin on blood cocarboxylase in **diabetes** mellitus.
AU SILIPRANDI N; NAVAIO F
SO Acta medica Scandinavica, (1952 Feb 23) Vol. 142, No. 2, pp. 147-8.
Journal code: 0370330. ISSN: 0001-6101.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5222-18917-109-135-230
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 303 OF 317 MEDLINE on STN

Full Text

AN 52042259 MEDLINE
DN PubMed ID: 14912149
TI [Effect of chlorhydrate of **thiamine** mono-, di-, and triphosphoric esters on intermediary carbohydrate metabolism in **diabetes** mellitus].
Azione del cloridrato e degli esteri mono-di-trifosforici della tiamina sul ricambio intermedio del carboidrati nel **diabete** mellito.
AU BUTTURINI U
SO Il Progresso medico, (1951 Dec 15) Vol. 7, No. 23, pp. 707-13.
Journal code: 2984827R. ISSN: 0370-1514.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5221-42741-110-409
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 304 OF 317 MEDLINE on STN

Full Text

AN 52040877 MEDLINE
DN PubMed ID: 14910767
TI Action of insulin on **thiamine** phosphorylation.
AU SILIPRANDI D; SILIPRANDI N
SO Nature, (1952 Feb 23) Vol. 169, No. 4295, pp. 329.
Journal code: 0410462. ISSN: 0028-0836.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5221-41359-110-191-409
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 305 OF 317 MEDLINE on STN

Full Text

AN 52039353 MEDLINE
DN PubMed ID: 14909243
TI [**Diabetic** acidosis and cocarboxylase].
Acidoses **diabetiques** graves et cocarboxylase.
AU MICHAUX P
SO Journal des sciences medicales de Lille, (1951 Dec 9) Vol. 69, No. 25, pp. 630-9.
Journal code: 0413413. ISSN: 0021-8111.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5221-39834-87-109
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 306 OF 317 MEDLINE on STN

Full Text

AN 52021344 MEDLINE
DN PubMed ID: 14891234
TI [Hypophysial **diabetes** and its therapy with **vitamin B1**].
A hypophysaer **diabetes** es kezelese B1 vitaminnat.
AU JULESZ M; ZSOLDOS I; SZATMARI E
SO Orvosi hetilap, (1951 Oct 28) Vol. 92, No. 43, pp. 1399-403.
Journal code: 0376412. ISSN: 0030-6002.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5221-21603-110-409
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 307 OF 317 MEDLINE on STN

Full Text

AN 52011882 MEDLINE
DN PubMed ID: 14881772
TI [Therapy of **diabetic** coma with cocarboxylase].
TRAITEMENT du coma **diabetique** par la cocarboxylase.
AU Anonymous
SO Medecine et hygiene, (1951 Sep 1) Vol. 9, No. 201, pp. 312.
Journal code: 9427226. ISSN: 0025-6749.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE; Dental Journals
OS CLML5221-12043-87-109
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 308 OF 317 MEDLINE on STN

Full Text

AN 52005218 MEDLINE
DN PubMed ID: 14875108
TI Cocarboxylase in experimental **diabetes**.
AU SILIPRANDI D; SILIPRANDI N
SO Nature, (1951 Sep 8) Vol. 168, No. 4271, pp. 422.
Journal code: 0410462. ISSN: 0028-0836.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5221-5220-87-109
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 309 OF 317 MEDLINE on STN

Full Text

AN 51073282 MEDLINE
DN PubMed ID: 14843732
TI [Cocarboxylase therapy of **diabetic** coma].
Le traitement du coma **diabetique** par la cocarboxylase.
AU BOULIN R; MEYER F; GUENIOT M; LAPRESLE C
SO Paris medical, (1951 Mar 10) Vol. 14, No. 10, pp. 129-31.
Journal code: 19520510R.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-76706-211-217-262
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 310 OF 317 MEDLINE on STN

Full Text

AN 51069059 MEDLINE
DN PubMed ID: 14839509
TI [Statistics on mortality from **diabetic** coma treated by cocarboxylase in 1950].
Statistique de la mortalite du coma **diabetique** traite par la cocarboxylase en 1950.
AU BOULIN R; MEYER F W; GUENIOT M; LAPRESLE C
SO Bulletins et memoires de la Societe medicale des hopitaux de Paris, (Mar 9-16 1951) Vol. 67, No. 9-10, pp. 347-8.
Journal code: 7503472. ISSN: 0366-1334.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-72386-211-263
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 311 OF 317 MEDLINE on STN

Full Text

AN 51068631 MEDLINE
DN PubMed ID: 14839081
TI [Influence of experimental **diabetes** on cocarboxylase of the liver and on its formation of **thiamine**].
Influenza del **diabete** sperimentale sulla cocarbossilasi del fegato e sulla sua formazione dalla tiamina.
AU SILIPRANDI D; SILIPRANDI N
SO Bollettino della Societa italiana di biologia sperimentale, (1950 Nov-Dec) Vol. 26, No. 11-12, pp. 1510-2.
Journal code: 7506962. ISSN: 0037-8771.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-71930-211-262-443
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 312 OF 317 MEDLINE on STN

Full Text

AN 51068630 MEDLINE
DN PubMed ID: 14839080
TI [Action of **thiamine** and diphosphothiamine on glycide metabolism in **diabetic** animals].
Azione della tiamina e della difosfotiamina sul ricambio glicidico degli animali **diabetici**.
AU SILIPRANDI N
SO Bollettino della Societa italiana di biologia sperimentale, (1950 Nov-Dec) Vol. 26, No. 11-12, pp. 1508-10.
Journal code: 7506962. ISSN: 0037-8771.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-71929-262-384-443
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 313 OF 317 MEDLINE on STN

Full Text

AN 51060549 MEDLINE
DN PubMed ID: 14830999
TI [Case of non-acidotic **diabetes** with juvenilism and Kimmelsteil-Wilson syndrome; cocarboxylase therapy].
Un cas de **diabete** non acidotique avec juvenilisme et syndrome de Kimmelsteil-Wilson; traitement par la cocarboxylase.
AU BENMUSSA; COHEN H; BOULAKIA Y; NAHUM A; PEREZ C
SO Bulletins et memoires de la Societe medicale des hopitaux de Paris, (Feb

9-16 1951) Vol. 67, No. 5-6, pp. 222-6.
Journal code: 7503472. ISSN: 0366-1334.

DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-63522-211-263-383
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 314 OF 317 MEDLINE on STN
Full Text
AN 51042841 MEDLINE
DN PubMed ID: 14813291
TI [Therapeutic use of di- and triphosphoric esters of **thiamine** in **diabetes mellitus**].
Sull'impiego terapeutico degli esteri die tri fosforico della tiamina nel **diabete mellito**.
AU SILIPRANDI N; TRAVERSO R
SO Farmaco (Societa chimica italiana : 1989), (1950 Nov-Dec) Vol. 5, No. 6, pp. 655-64.
Journal code: 8912641. ISSN: 0014-827X.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-44943-263-443
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 315 OF 317 MEDLINE on STN
Full Text
AN 51033438 MEDLINE
DN PubMed ID: 14803888
TI [Coccarboxylase treatment of **diabetic** coma].
La cocarboxylase dans le traitement du coma **diabetique**.
AU AUBERTIN E
SO Journal de medecine de Bordeaux et du Sud-Ouest, (1950 Nov) Vol. 127, No. 11, pp. 763-4.
Journal code: 0161067. ISSN: 0368-3001.
DT Journal; Article; (JOURNAL ARTICLE)
LA UNSPECIFIED
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-35108-211-262
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 316 OF 317 MEDLINE on STN
Full Text
AN 51021628 MEDLINE
DN PubMed ID: 14792078
TI Raised blood pyruvic acid level in **diabetic** acidosis; the value of cocarboxylase in treatment.
AU GILLILAND I C; MARTIN M M
SO British medical journal, (1951 Jan 6) Vol. 1, No. 4696, pp. 14-6.
Journal code: 0372673. ISSN: 0007-1447.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS OLDMEDLINE; NONMEDLINE
OS CLML5120-22760-211-212-262
EM 200402
ED Entered STN: Mar 2004
Last Updated on STN: Mar 2004
Entered Medline: 15 Feb 2004

L29 ANSWER 317 OF 317 MEDLINE on STN
Full Text
AN 50036586 MEDLINE

DN PubMed ID: 15426954
 TI [Results of treatment of 32 cases of **diabetic** coma by cocarboxylase associated with insulin].
 Resultats du traitement de 32 cas de coma **diabetique** par la cocarboxylase associee a l'insuline; deuxieme note.
 AU BOULIN R; UHRY P; NEPVEUX F; MEYER F W
 SO Bulletins et memoires de la Societe medicale des hopitaux de Paris, (Jun 2-9 1950) Vol. 66, No. 19-20, pp. 970-1.
 Journal code: 7503472. ISSN: 0366-1334.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA UNSPECIFIED
 FS OLDMEDLINE; NONMEDLINE
 OS CLML5019-17256-65-262
 EM 200409
 ED Entered STN: Oct 2004
 Last Updated on STN: Oct 2004
 Entered Medline: 30 Sep 2004

=> file ca		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.85	63.79

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jun 2007 VOL 146 ISS 25.
 FILE LAST UPDATED: 7 Jun 2007 (20070607/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

	E VITAMIN B1/CN
L1	1 S E3
	E PIOGLITAZONE/CN
L2	1 S E3
	E ROSIGLITAZONE/CN
L3	1 S E3
	E CS-011/CN
	E CS 011/CN
L4	1 S E3
	E TAK 559/CN
L5	1 S E3
	E FK 614/CN
L6	1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

L7	1 S L1
L8	1 S L2
L9	1 S L3

L10 0 S L4
L11 0 S L5
L12 0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

L13 7457 S L1
L14 12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15 13000 S L13 OR L14
L16 1041 S L2
L17 1426 S PIOGLITAZONE
L18 1426 S L16 OR L17
L19 1361 S L3
L20 1891 S ROSIGLITAZONE
L21 1891 S L19 OR L20
L22 0 S CS-011
L23 5 S (TAK-559 OR FK-614)
L24 0 S L15 AND L18
L25 0 S L14 AND L21
L26 0 S L14 AND L23
L27 286036 S DIABET?
L28 0 S L15 AND L21
L29 317 S L15 AND L27

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

=> s 13
L30 1975 L3

=> s 14
L31 9 L4

=> s 15
L32 19 L5

=> s 16
L33 23 L6

=> s 11
L34 23452 L1

=> s 131 and 134
L35 1 L31 AND L34

=> d

L35 ANSWER 1 OF 1 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:309959 CA
TI Medicinal composition
IN Kawasugi, Kaname
PA Japan
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027967	A1	20050331	WO 2003-JP11847	20030917
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003266526	A1	20050411	AU 2003-266526	20030917
	US 2007105910	A1	20070510	US 2006-572557	20060317
PRAI	WO 2003-JP11847	A	20030917		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 132 and 134
L36 1 L32 AND L34

=> s 133 and 134
L37 1 L33 AND L34

=> d

L37 ANSWER 1 OF 1 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:309959 CA
TI Medicinal composition
IN Kawasugi, Kaname
PA Japan
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027967	A1	20050331	WO 2003-JP11847	20030917
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003266526	A1	20050411	AU 2003-266526	20030917
	US 2007105910	A1	20070510	US 2006-572557	20060317
PRAI	WO 2003-JP11847	A	20030917		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

L1 1 S E3
E VITAMIN B1/CN
L2 1 S E3
E PIOGLITAZONE/CN
L3 1 S E3
E ROSIGLITAZONE/CN
E CS-011/CN
L4 1 S E3
E CS 011/CN
E TAK 559/CN
L5 1 S E3
E FK 614/CN
L6 1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

L7 1 S L1
L8 1 S L2
L9 1 S L3
L10 0 S L4
L11 0 S L5
L12 0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

L13 7457 S L1

L14 12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
 L15 13000 S L13 OR L14
 L16 1041 S L2
 L17 1426 S PIOGLITAZONE
 L18 1426 S L16 OR L17
 L19 1361 S L3
 L20 1891 S ROSIGLITAZONE
 L21 1891 S L19 OR L20
 L22 0 S CS-011
 L23 5 S (TAK-559 OR FK-614)
 L24 0 S L15 AND L18
 L25 0 S L14 AND L21
 L26 0 S L14 AND L23
 L27 286036 S DIABET?
 L28 0 S L15 AND L21
 L29 317 S L15 AND L27

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

L30 1975 S L3
 L31 9 S L4
 L32 19 S L5
 L33 23 S L6
 L34 23452 S L1
 L35 1 S L31 AND L34
 L36 1 S L32 AND L34
 L37 1 S L33 AND L34

=> s diabet?/ab,bi
 111607 DIABET?/AB
 133460 DIABET?/BI
 L38 133460 DIABET?/AB,BI

=> s l34 and l38
 L39 355 L34 AND L38

=> d l31 1-9

L31 ANSWER 1 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:804 CA
 TI insulin sensitization for delaying puberty and increasing growth
 IN De Zegher, Francis; Dunger, David; Ibanez, Lourdes
 PA K.U. Leuven Research and Development, Belg.; Addenbrooke's Hospital
 SO PCT Int. Appl., 61pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006125285	A1	20061130	WO 2006-BE60	20060523
	WO 2006125285	B1	20070111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2005-10469	A	20050523		
OS	MARPAT 146:804				
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD			
		ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L31 ANSWER 2 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:198849 CA

TI Novel dosage form comprising modified-release and immediate-release active ingredients
 IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
 PA India
 SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 2004096499	A1	20040520	US 2003-630446	20030729
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		

L31 ANSWER 3 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:135217 CA
 TI Pharmaceutical compositions containing bezafibrate and analogs and diflunisal and its analog for the treatment of metabolic disorders
 IN Lee, Margaret S.; Zimmerman, Grant R.; Finelli, Alyce Lynn; Grau, Daniel; Keith, Curtis; Nichols, M. James
 PA Combinatorx, Incorporated, USA
 SO PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006004803	A1	20060112	WO 2005-US23030	20050629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005259864	A1	20060112	AU 2005-259864	20050629
	CA 2571683	A1	20060112	CA 2005-2571683	20050629
	EP 1781303	A1	20070509	EP 2005-768186	20050629
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	US 2006069161	A1	20060330	US 2005-171566	20050630
PRAI	US 2004-584380P	P	20040630		
	US 2005-649329P	P	20050202		
	WO 2005-US23030	W	20050629		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 4 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:326098 CA
 TI Preparation of tetrahydronaphthalenylcarboxamide derivatives as RXR (retinoid X receptor) function modulators and RXR/PPAR heterodimer function modulators
 IN Ikeshita, Shinji; Yamamoto, Junji; Shinohara, Masashi

PA Sakai Chemical Industry Co., Ltd., Japan
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087713	A1	20050922	WO 2005-JP4357	20050311
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	JP 2004-71741	A	20040312		
OS	MARPAT 143:326098				
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L31 ANSWER 5 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:309959 CA
TI Medicinal composition
IN Kawasugi, Kaname
PA Japan
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027967	A1	20050331	WO 2003-JP11847	20030917
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003266526	A1	20050411	AU 2003-266526	20030917
	US 2007105910	A1	20070510	US 2006-572557	20060317
PRAI	WO 2003-JP11847	A	20030917		
RE.CNT	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L31 ANSWER 6 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:273138 CA
TI Research progress in peroxisome proliferator-activated receptor gamma agonists
AU Cheng, Feng; Shen, Jianhua; Luo, Xiaomin; Shen, Jingkang; Yang, Yiming; Shen, Xu; Jiang, Hualiang
CS Center for Drug Discovery + Design, State Key Laboratory of New Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaowu Huaxue Zazhi (2003), 13(2), 110-118, 124
CODEN: ZYHZEJ; ISSN: 1005-0108
PB Zhongguo Yaowu Huaxue Zazhi Bianjibu
DT Journal; General Review
LA Chinese

L31 ANSWER 7 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 141:47336 CA
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones
IN Knudsen, Lotte Bjerre
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050115	A2	20040617	WO 2003-DK824	20031201
	WO 2004050115	A3	20040722		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU	2003283216	A1	20040623	AU 2003-283216	20031201
EP	1569682	A2	20050907	EP 2003-775117	20031201
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
EP	1688148	A1	20060809	EP 2006-112986	20031201
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK			
US	2004180824	A1	20040916	US 2003-726734	20031203
US	2006189535	A1	20060824	US 2006-414114	20060428
PRAI	DK 2002-1864	A	20021203		
	US 2002-431999P	P	20021209		
	EP 2003-775117	A3	20031201		
	WO 2003-DK824	W	20031201		
	US 2003-726734	B1	20031203		

L31 ANSWER 8 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 139:111706 CA
TI peroxisome proliferator-activated receptor- α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them
IN Needleman, Philip
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003059271	A2	20030724	WO 2003-US1099	20030114
	WO 2003059271	A3	20031127		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US	2003220374	A1	20031127	US 2003-341174	20030113
CA	2472199	A1	20030724	CA 2003-2472199	20030114
AU	2003207557	A1	20030730	AU 2003-207557	20030114
AU	2003207557	A2	20030730		
EP	1465621	A2	20041013	EP 2003-705768	20030114

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1642544	A	20050720	CN 2003-805886	20030114
BR 2003006872	A	20050906	BR 2003-6872	20030114
JP 2006501136	T	20060112	JP 2003-559436	20030114
ZA 2004005562	A	20051004	ZA 2004-5562	20040713
PRAI US 2002-348298P	P	20020114		
US 2003-341174	A	20030113		
WO 2003-US1099	W	20030114		
OS MARPAT 139:111706				

L31 ANSWER 9 OF 9 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 138:362697 CA
 TI Pharmaceutical composition containing a glitazone and a thiazolidinedione derivative, and its use to treat diabetes
 IN Moinet, Gerard; Botton, Gerard; Mesangeau, Didier
 PA Lipha, Fr.
 SO Fr. Demande, 24 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	FR 2832064	A1	20030516	FR 2001-14676	20011113	
	WO 2003041706	A1	20030522	WO 2002-EP11660	20021018	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2002350563	A1	20030526	AU 2002-350563	20021018	
PRAI	FR 2001-14676	A	20011113			
	WO 2002-EP11660	W	20021018			

OS MARPAT 138:362697

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

	E VITAMIN B1/CN
L1	1 S E3
	E PIOGLITAZONE/CN
L2	1 S E3
	E ROSIGLITAZONE/CN
L3	1 S E3
	E CS-011/CN
	E CS 011/CN
L4	1 S E3
	E TAK 559/CN
L5	1 S E3
	E FK 614/CN
L6	1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

L7	1 S L1
L8	1 S L2
L9	1 S L3
L10	0 S L4
L11	0 S L5
L12	0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

L13 7457 S L1
L14 12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15 13000 S L13 OR L14
L16 1041 S L2
L17 1426 S PIOGLITAZONE
L18 1426 S L16 OR L17
L19 1361 S L3
L20 1891 S ROSIGLITAZONE
L21 1891 S L19 OR L20
L22 0 S CS-011
L23 5 S (TAK-559 OR FK-614)
L24 0 S L15 AND L18
L25 0 S L14 AND L21
L26 0 S L14 AND L23
L27 286036 S DIABET?
L28 0 S L15 AND L21
L29 317 S L15 AND L27

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

L30 1975 S L3
L31 9 S L4
L32 19 S L5
L33 23 S L6
L34 23452 S L1
L35 1 S L31 AND L34
L36 1 S L32 AND L34
L37 1 S L33 AND L34
L38 133460 S DIABET?/AB,BI
L39 355 S L34 AND L38

=> d l32 1-19

L32 ANSWER 1 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:288455 CA
TI Therapeutic agent for diabetes containing insulin resistance improving agent
IN Kanda, Shoichi; Araki, Kazushi; Ohsumi, Jun
PA Sankyo Company, Limited, Japan
SO U.S. Pat. Appl. Publ., 17pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007049515	A1	20070301	US 2006-525481	20060922
	WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2004-94598	A	20040329		
	WO 2005-JP5526	A2	20050325		

L32 ANSWER 2 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:134463 CA
TI Discontinued drugs in 2005: endocrine and metabolic
AU Colca, Jerry R.
CS Kalamazoo Metabolic Research, Kalamazoo, MI, 49007, USA
SO Expert Opinion on Investigational Drugs (2007), 16(2), 129-136
CODEN: EOIDER; ISSN: 1354-3784
PB Informa Healthcare

DT Journal; General Review

LA English

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 3 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:93539 CA

TI Cyclic amine derivative containing PPAR regulator

IN Nishi, Takahide; Shimozato, Takaichi; Kagari, Takashi; Doi, Hiromi

PA Sankyo Company, Limited, Japan

SO PCT Int. Appl., 50pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006137509	A1	20061228	WO 2006-JP312568	20060623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2005-185287 A 20050624

OS MARPAT 146:93539

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 4 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:230614 CA

TI Preparation of benzisoxazole derivatives as novel LXR ligands useful in treatment of dyslipidemic diseases

IN Adams, Alan D.; Huang, Shaei Y.; Szewczyk, Jason W.

PA USA

SO U.S. Pat. Appl. Publ., 58pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006178398	A1	20060810	US 2005-226782	20050914
PRAI	US 2004-610518P	P	20040916		
OS	MARPAT 145:230614				

L32 ANSWER 5 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:318586 CA

TI Therapeutic agent for keratoconjunctiva disorder

IN Nakamura, Masatsugu; Hirai, Shinichiro; Shibagaki, Keiichi

PA Santen Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006030753	A1	20060323	WO 2005-JP16788	20050913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

CA 2579490 A1 20060323 CA 2005-2579490 20050913
 JP 2006104199 A 20060420 JP 2005-264528 20050913
 EP 1790338 A1 20070530 EP 2005-783155 20050913

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI JP 2004-265197 A 20040913
 WO 2005-JP16788 W 20050913

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 6 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:198849 CA
 TI Novel dosage form comprising modified-release and immediate-release active
 ingredients
 IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
 PA India
 SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 2004096499	A1	20040520	US 2003-630446	20030729
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		

L32 ANSWER 7 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:353392 CA
 TI Therapeutic agent for diabetes containing insulin resistance improving
 agent
 IN Kanda, Shoichi; Araki, Kazushi
 PA Sankyo Company, Limited, Japan; Ohsumi, Jun
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2560928	A1	20051006	CA 2005-2560928	20050325

JP 2005314380 A 20051110 JP 2005-88634 20050325
 EP 1731170 A1 20061213 EP 2005-726976 20050325
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN 1972715 A 20070530 CN 2005-80016581 20050325
 US 2007049515 A1 20070301 US 2006-525481 20060922
 PRAI JP 2004-94598 A 20040329
 WO 2005-JP5526 W 20050325
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 8 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:326098 CA
 TI Preparation of tetrahydronaphthalenylcarboxamide derivatives as RXR
 (retinoid X receptor) function modulators and RXR/PPAR heterodimer
 function modulators
 IN Ikeshita, Shinji; Yamamoto, Junji; Shinohara, Masashi
 PA Sakai Chemical Industry Co., Ltd., Japan
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005087713	A1	20050922	WO 2005-JP4357	20050311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI JP 2004-71741	A	20040312		

OS MARPAT 143:326098
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 9 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:309959 CA
 TI Medicinal composition
 IN Kawasugi, Kaname
 PA Japan
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005027967	A1	20050331	WO 2003-JP11847	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003266526	A1	20050411	AU 2003-266526	20030917
US 2007105910	A1	20070510	US 2006-572557	20060317
PRAI WO 2003-JP11847	A	20030917		
RE.CNT 9				

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 10 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:148357 CA

TI A potent activator of PPAR α and γ reduces the vascular cell recruitment and inhibits the intimal thickening in hypercholesterolemic rabbits

AU Seki, Naoto; Bujo, Hideaki; Jiang, Meizi; Shibasaki, Manabu; Takahashi, Kazuo; Hashimoto, Naotake; Saito, Yasushi

CS Department of Clinical Cell Biology (F5), Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan

SO Atherosclerosis (Amsterdam, Netherlands) (2005), 178(1), 1-7

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier B.V.

DT Journal

LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 11 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 141:64840 CA

TI A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes

AU Sakamoto, Junichi; Kimura, Hiroyuki; Moriyama, Shinji; Imoto, Hiroshi; Momose, Yu; Odaka, Hiroyuki; Sawada, Hidekazu

CS Pharmaceutical Discovery Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan

SO European Journal of Pharmacology (2004), 495(1), 17-26

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 12 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 141:925 CA

TI Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559

AU Imoto, Hiroshi; Matsumoto, Mitsuharu; Odaka, Hiroyuki; Sakamoto, Junichi; Kimura, Hiroyuki; Nonaka, Masami; Kiyota, Yutaka; Momose, Yu

CS Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SO Chemical & Pharmaceutical Bulletin (2004), 52(1), 120-124

CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

OS CASREACT 141:925

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 13 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 140:309422 CA

TI Solid preparations containing biguanides and insulin resistance-improving agents

IN Koike, Masahiko; Koyama, Hiroyoshi; Hamaguchi, Naoru

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004030700	A1	20040415	WO 2003-JP12781	20031006
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2501587	A1	20040415	CA 2003-2501587	20031006
AU 2003271103	A1	20040423	AU 2003-271103	20031006
JP 2004149521	A	20040527	JP 2003-346699	20031006
EP 1561472	A1	20050810	EP 2003-751344	20031006

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003015082	A	20050816	BR 2003-15082	20031006
CN 1717253	A	20060104	CN 2003-80104419	20031006
US 2005287207	A1	20051229	US 2005-530262	20050405
IN 2005KN00819	A	20060609	IN 2005-KN819	20050505
NO 2005002239	A	20050629	NO 2005-2239	20050506

PRAI JP 2002-294045 A 20021007
 WO 2003-JP12781 W 20031006

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 14 OF 19 CA COPYRIGHT 2007 ACS on STN
Full Text
 AN 139:276837 CA
 TI Studies on non-thiazolidinedione antidiabetic agents. 2. Novel
 oxyminoalkanoic acid derivatives as potent glucose and lipid lowering
 agents
 AU Imoto, Hiroshi; Sugiyama, Yasuo; Kimura, Hiroyuki; Momose, Yu
 CS Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka,
 532-8686, Japan
 SO Chemical & Pharmaceutical Bulletin (2003), 51(2), 138-151
 CODEN: CPBTAL; ISSN: 0009-2363
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 OS CASREACT 139:276837
 RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 15 OF 19 CA COPYRIGHT 2007 ACS on STN
Full Text
 AN 137:346207 CA
 TI ABC expression promoters
 IN Sugiyama, Yasuo; Fuse, Hiromitsu; Hiramata, Masao; Tozawa, Ryuichi
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002087580	A1	20021107	WO 2002-JP4072	20020424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,				
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2445322	A1	20021107	CA 2002-2445322	20020424
AU 2002251530	A1	20021111	AU 2002-251530	20020424
JP 2003012551	A	20030115	JP 2002-122349	20020424
EP 1382336	A1	20040121	EP 2002-720584	20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004077689	A1	20040422	US 2003-468433	20031016
PRAI JP 2001-128222	A	20010425		

WO 2002-JP4072 W 20020424
 OS MARPAT 137:346207
 RE.CNT 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 16 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 135:267220 CA
 TI Neovascularization inhibitors
 IN Hazama, Masatoshi; Miyazaki, Takeshi; Sugiyama, Yasuo
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001072695	A1	20011004	WO 2001-JP2447	20010327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: DE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DH, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001044562	A5	20011008	AU 2001-44562	20010327
JP 2001342135	A	20011211	JP 2001-89998	20010327
CA 2403903	A1	20020926	CA 2001-2403903	20010327
EP 1277730	A1	20030122	EP 2001-917499	20010327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003134884	A1	20030717	US 2002-239749	20020926
PRAI JP 2000-92966	A	20000328		
WO 2001-JP2447	W	20010327		

OS MARPAT 135:267220
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 17 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 134:361377 CA
 TI Body weight gain inhibitors
 IN Sugiyama, Yasuo; Odaka, Hiroyuki; Kimura, Hiroyuki
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001034200	A1	20010517	WO 2000-JP7879	20001109
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2390932	A1	20010517	CA 2000-2390932	20001109
AU 2001013033	A5	20010606	AU 2001-13033	20001109
JP 2001199887	A	20010724	JP 2000-347464	20001109
HU 200203837	A2	20030328	HU 2002-3837	20001109
EP 1304121	A1	20030423	EP 2000-974859	20001109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 200202214	A	20020709	NO 2002-2214	20020508
US 2005239854	A1	20051027	US 2005-168357	20050629
PRAI JP 1999-320319	A	19991110		

WO 2000-JP7879 W 20001109
 US 2002-129704 B1 20020509
 OS MARPAT 134:361377
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 18 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 134:326524 CA
 TI Process for the preparation of oxyiminoalkanoic acid ether derivatives
 IN Yamane, Taihei; Inagaki, Atsushi; Yabe, Osamu
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001032608	A1	20010510	WO 2000-JP7481	20001026
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389208	A1	20010510	CA 2000-2389208	20001026
AU 2000079580	A	20010514	AU 2000-79580	20001026
EP 1227081	A1	20020731	EP 2000-970080	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001192376	A	20010717	JP 2000-333547	20001027
US 6518435	B1	20030211	US 2002-111480	20020425
PRAI JP 1999-308345	A	19991029		
WO 2000-JP7481	W	20001026		
OS CASREACT 134:326524; MARPAT 134:326524				
RE.CNT 6				
THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L32 ANSWER 19 OF 19 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 131:351319 CA
 TI Oxazolylmethoxybenzyl oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
 IN Momose, Yu; Odaka, Hiroyuki; Imoto, Hiroshi; Kimura, Hiroyuki; Sakamoto, Junichi
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958510	A1	19991118	WO 1999-JP2407	19990510
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9936297	A	19991129	AU 1999-36297	19990510
AU 766831	B2	20031023		
BR 9910371	A	20010109	BR 1999-10371	19990510
EP 1077957	A1	20010228	EP 1999-918355	19990510
EP 1077957	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200003299	T2	20010521	TR 2000-200003299	19990510

HU 200103714	A2	20020128	HU 2001-3714	19990510
NZ 508066	A	20030328	NZ 1999-508066	19990510
RU 2213738	C2	20031010	RU 2000-131183	19990510
EP 1428531	A1	20040616	EP 2004-75569	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 272625	T	20040815	AT 1999-918355	19990510
PT 1077957	T	20041029	PT 1999-918355	19990510
ES 2226377	T3	20050316	ES 1999-918355	19990510
JP 2000034266	A	20000202	JP 1999-130543	19990511
JP 3074532	B2	20000807		
JP 2000198772	A	20000718	JP 1999-373202	19990511
US 6251926	B1	20010626	US 1999-423854	19991115
IN 2000KN00434	A	20050311	IN 2000-KN434	20001024
ZA 2000006121	A	20010518	ZA 2000-6121	20001030
LV 12606	B	20010520	LV 2000-148	20001101
NO 2000005531	A	20010105	NO 2000-5531	20001102
NO 317426	B1	20041025		
US 6495581	B1	20021217	US 2000-714699	20001116
HK 1034972	A1	20050311	HK 2001-105750	20010815
US 2003186985	A1	20031002	US 2002-331056	20021227
US 6924300	B2	20050802		
PRAI JP 1998-127921	A	19980511		
JP 1998-127922	A	19980511		
EP 1999-918355	A3	19990510		
WO 1999-JP2407	W	19990510		
JP 1999-130543	A3	19990511		
US 1999-423854	A3	19991115		
US 2000-714699	A3	20001116		
OS MARPAT 131:351319				
RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

	E VITAMIN B1/CN
L1	1 S E3
	E PIOGLITAZONE/CN
L2	1 S E3
	E ROSIGLITAZONE/CN
L3	1 S E3
	E CS-011/CN
	E CS 011/CN
L4	1 S E3
	E TAK 559/CN
L5	1 S E3
	E FK 614/CN
L6	1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

L7	1 S L1
L8	1 S L2
L9	1 S L3
L10	0 S L4
L11	0 S L5
L12	0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

L13	7457 S L1
L14	12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15	13000 S L13 OR L14
L16	1041 S L2
L17	1426 S PIOGLITAZONE
L18	1426 S L16 OR L17
L19	1361 S L3
L20	1891 S ROSIGLITAZONE
L21	1891 S L19 OR L20
L22	0 S CS-011

L23 5 S (TAK-559 OR FK-614)
 L24 0 S L15 AND L18
 L25 0 S L14 AND L21
 L26 0 S L14 AND L23
 L27 286036 S DIABET?
 L28 0 S L15 AND L21
 L29 317 S L15 AND L27

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

L30 1975 S L3
 L31 9 S L4
 L32 19 S L5
 L33 23 S L6
 L34 23452 S L1
 L35 1 S L31 AND L34
 L36 1 S L32 AND L34
 L37 1 S L33 AND L34
 L38 133460 S DIABET?/AB,BI
 L39 355 S L34 AND L38

=> d 133 1-23

L33 ANSWER 1 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:288455 CA
 TI Therapeutic agent for diabetes containing insulin resistance improving agent
 IN Kanda, Shoichi; Araki, Kazushi; Ohsumi, Jun
 PA Sankyo Company, Limited, Japan
 SO U.S. Pat. Appl. Publ., 17pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007049515	A1	20070301	US 2006-525481	20060922
	WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2004-94598	A	20040329		
	WO 2005-JP5526	A2	20050325		

L33 ANSWER 2 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:134463 CA
 TI Discontinued drugs in 2005: endocrine and metabolic
 AU Colca, Jerry R.
 CS Kalamazoo Metabolic Research, Kalamazoo, MI, 49007, USA
 SO Expert Opinion on Investigational Drugs (2007), 16(2), 129-136
 CODEN: EOIDER; ISSN: 1354-3784
 PB Informa Healthcare
 DT Journal; General Review
 LA English
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 3 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 146:128685 CA
 TI Pharmaceutical compositions containing PPAR γ agonist for decreasing blood lactic acid content
 IN Okuno, Akira; Yoshida, Taishi; Ogawa, Junko

PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 25pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007007757	A1	20070118	WO 2006-JP313775	20060711
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2005-202601 A 20050712

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 4 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:328394 CA
TI Roflumilast for the treatment of diabetes mellitus
IN Kley, Hans-Peter; Hanauer, Guido; Hauser, Daniela; Schmidt, Beate; Bredenbroeker, Dirk; Wurst, Wilhelm; Kemkowski, Joerg
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 67pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006094942	A1	20060914	WO 2006-EP60445	20060303
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2005-101780 A 20050308

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:328392 CA
TI Roflumilast for the treatment of diabetes mellitus and accompanying disorders, and combinations with other agents
IN Kley, Hans-Peter; Hanauer, Guido; Hauser, Daniela; Schmidt, Beate; Bredenbroeker, Dirk; Wurst, Wilhelm; Kemkowski, Joerg
PA Altana Pharma AG, Germany
SO PCT Int. Appl., 71pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006094933	A1	20060914	WO 2006-EP60418	20060303

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-101772 A 20050308

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:241425 CA

TI A selective peroxisome proliferator-activated receptor γ modulator with distinct fat cell regulation properties

AU Fujimura, Takao; Kimura, Chiaki; Oe, Tomoya; Takata, Yoko; Sakuma, Hiroyuki; Aramori, Ichiro; Mutoh, Seitaro

CS Pharmacology Research Laboratories, Astellas Pharma Inc., Osaka, Japan

SO Journal of Pharmacology and Experimental Therapeutics (2006), 318(2), 863-871

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 145:161649 CA

TI Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor γ

AU Fujimura, Takao; Sakuma, Hiroyuki; Ohkubo-Suzuki, Akiko; Aramori, Ichiro; Mutoh, Seitaro

CS Pharmacology Research Laboratories, Astellas Pharma Inc., 2-1-6 Kashima, Yodogawa-ku, Osaka, 532-8514, Japan

SO Biological & Pharmaceutical Bulletin (2006), 29(3), 423-429

CODEN: BPBLEO; ISSN: 0918-6158

PB Pharmaceutical Society of Japan

DT Journal

LA English

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 8 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:198849 CA

TI Novel dosage form comprising modified-release and immediate-release active ingredients

IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar

PA India

SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006024365	A1	20060202	US 2005-134633	20050519
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 2004096499	A1	20040520	US 2003-630446	20030729

PRAI IN 2002-MU697 A 20020805
 IN 2002-MU699 A 20020805
 IN 2003-MU80 A 20030122
 IN 2003-MU82 A 20030122
 US 2003-630446 A2 20030729

L33 ANSWER 9 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:135217 CA
 TI Pharmaceutical compositions containing bezafibrate and analogs and
 diflunisal and its analog for the treatment of metabolic disorders
 IN Lee, Margaret S.; Zimmerman, Grant R.; Finelli, Alyce Lynn; Grau, Daniel;
 Keith, Curtis; Nichols, M. James
 PA Combinatorx, Incorporated, USA
 SO PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006004803	A1	20060112	WO 2005-US23030	20050629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005259864	A1	20060112	AU 2005-259864	20050629
	CA 2571683	A1	20060112	CA 2005-2571683	20050629
	EP 1781303	A1	20070509	EP 2005-768186	20050629
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	US 2006069161	A1	20060330	US 2005-171566	20050630
PRAI	US 2004-584380P	P	20040630		
	US 2005-649329P	P	20050202		
	WO 2005-US23030	W	20050629		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 10 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 144:80973 CA
 TI FK614, a novel peroxisome proliferator-activated receptor γ
 modulator, induces differential transactivation through a unique
 ligand-specific interaction with transcriptional coactivators
 AU Fujimura, Takao; Sakuma, Hiroyuki; Konishi, Satoko; Oe, Tomoya; Hosogai,
 Naomi; Kimura, Chiaki; Aramori, Ichiro; Mutoh, Seitaro
 CS Pharmacology Research Laboratories, Astellas Pharma Inc., Yodogawa-ku,
 Osaka, 532-8514, Japan
 SO Journal of Pharmacological Sciences (Tokyo, Japan) (2005), 99(4), 342-352
 CODEN: JPSTGJ; ISSN: 1347-8613
 PB Japanese Pharmacological Society
 DT Journal
 LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 11 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:353392 CA
 TI Therapeutic agent for diabetes containing insulin resistance improving
 agent
 IN Kanda, Shoichi; Araki, Kazushi
 PA Sankyo Company, Limited, Japan; Ohsumi, Jun

SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2560928	A1	20051006	CA 2005-2560928	20050325
	JP 2005314380	A	20051110	JP 2005-88634	20050325
	EP 1731170	A1	20061213	EP 2005-726976	20050325
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1972715	A	20070530	CN 2005-80016581	20050325
	US 2007049515	A1	20070301	US 2006-525481	20060922
PRAI	JP 2004-94598	A	20040329		
	WO 2005-JP5526	W	20050325		
RE.CNT	10	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L33 ANSWER 12 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:326098 CA
 TI Preparation of tetrahydronaphthalenylcarboxamide derivatives as RXR (retinoid X receptor) function modulators and RXR/PPAR heterodimer function modulators
 IN Ikeshita, Shinji; Yamamoto, Junji; Shinohara, Masashi
 PA Sakai Chemical Industry Co., Ltd., Japan
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087713	A1	20050922	WO 2005-JP4357	20050311
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2004-71741	A	20040312		
OS	MARPAT 143:326098				
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L33 ANSWER 13 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:298863 CA
 TI FK-614, a selective peroxisome proliferator-activated receptor γ agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs
 AU Uchino, Hiroshi; Kim, Tony; Lam, Tony K. T.; Yoshii, Hidenori; Klement, Peter; Williams, Wendy; Kawamori, Ryuzo; Giacca, Adria
 CS Department of Physiology, University of Toronto, Toronto, ON, M5S 1A8,

Can.
 SO Metabolism, Clinical and Experimental (2005), 54(9), 1250-1258
 CODEN: METAJ; ISSN: 0026-0495
 PB Elsevier Inc.
 DT Journal
 LA English
 RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:272565 CA
 TI pharmaceutical combination comprising a sulfonamide
 IN Kayakiri, Hiroshi; Kato, Takeshi; Minoura, Hideaki; Hirosumi, Jiro
 PA Fujisawa Pharmaceutical Co. Ltd., Japan
 SO U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005197376	A1	20050908	US 2005-68747	20050302
	WO 2005082414	A2	20050909	WO 2005-JP4022	20050302
	WO 2005082414	A3	20060629		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	JP 2004-57555	A	20040302		
OS	MARPAT 143:272565				

L33 ANSWER 15 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 143:260044 CA
 TI Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor γ agonist, on insulin resistance in Zucker fatty rat
 AU Minoura, Hideaki; Takeshita, Shigeru; Yamamoto, Tadashi; Mabuchi, Miyuki; Hirosumi, Jiro; Takakura, Shoji; Kawamura, Ikuo; Seki, Jiro; Manda, Toshitaka; Ita, Makoto; Mutoh, Seitaro
 CS Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Yodogawa-ku, Osaka, 532-8514, Japan
 SO European Journal of Pharmacology (2005), 519(1-2), 182-190
 CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier B.V.
 DT Journal
 LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 16 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 142:309959 CA
 TI Medicinal composition
 IN Kawasugi, Kaname
 PA Japan
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027967	A1	20050331	WO 2003-JP11847	20030917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003266526 A1 20050411 AU 2003-266526 20030917
 US 2007105910 A1 20070510 US 2006-572557 20060317
 PRAI WO 2003-JP11847 A 20030917
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 17 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 141:47086 CA
 TI Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614
 AU Minoura, Hideaki; Takeshita, Shigeru; Ita, Makoto; Hirosumi, Jiro; Mabuchi, Miyuki; Kawamura, Ikuo; Nakajima, Satoko; Nakayama, Osamu; Kayakiri, Hiroshi; Oku, Teruo; Ohkubo-Suzuki, Akiko; Fukagawa, Masao; Kojo, Hitoshi; Hanioka, Kenichi; Yamasaki, Noritsugu; Imoto, Takafumi; Kobayashi, Yoshinori; Mutoh, Seitaro
 CS Research Division, Fujisawa Pharmaceutical Co., Ltd., 2-1-6, Kashima, Osaka, Yodogawa, 532-8514, Japan
 SO European Journal of Pharmacology (2004), 494(2-3), 273-281
 CODEN: EJPHAZ; ISSN: 0014-2999
 PB Elsevier
 DT Journal
 LA English
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 18 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 140:105294 CA
 TI Method of screening for antidiabetic agents
 IN Fujimura, Takao; Sakuma, Hiroyuki; Kimura, Chiaki; Oe, Tomoya; Aramori, Ichiro
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005550	A2	20040115	WO 2003-JP8523	20030704
	WO 2004005550	A3	20040415		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003245051	A1	20040123	AU 2003-245051	20030704
PRAI	AU 2002-3378	A	20020704		
	WO 2003-JP8523	W	20030704		

L33 ANSWER 19 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 136:183821 CA
 TI Preparation of benzimidazole derivatives for inhibiting neoplastic cells
 IN Sperl, Gerhard; Pamukcu, Rifat; Ixkes, Ulrich; Piazza, Gary A.
 PA Cell Pathways, Inc., USA

SO U.S., 54 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6348032	B1	20020219	US 1998-199094	19981123
	US 2002082280	A1	20020627	US 2001-12672	20011105
PRAI	US 1998-199094	A3	19981123		
OS	MARPAT 136:183821				

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 20 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 136:177977 CA
 TI Methods for treating inflammatory diseases using PPAR agonists
 IN Pershadsingh, Harrihar A.
 PA USA
 SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002013812	A1	20020221	WO 2001-US25668	20010816
	W: AU, CA, MX, NZ, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001088271	A5	20020225	AU 2001-88271	20010816
PRAI	US 2000-225907P	P	20000817		
	US 2000-230509P	P	20000906		
	WO 2001-US25668	W	20010816		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 21 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 132:355058 CA
 TI Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide
 IN Murai, Yoshiyuki; Yamasaki, Noritsugu; Imoto, Takafumi; Nishikawa, Masahiro; Mititsu, Kunihiko
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; Daicel Chemical Industries, Ltd.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000029383	A1	20000525	WO 1999-JP6296	19991111
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2350520	A1	20000525	CA 1999-2350520	19991111
	BR 9915315	A	20010807	BR 1999-15315	19991111
	EP 1138674	A1	20011004	EP 1999-972205	19991111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 200104029	A2	20020529	HU 2001-4029	19991111
	AU 764594	B2	20030821	AU 2000-11783	19991111
	CN 1136195	B	20040128	CN 1999-814325	19991111
	RU 2228931	C2	20040520	RU 2001-116105	19991111
	IN 2001CN00800	A	20050304	IN 2001-CN800	20010612

US 6703410 B1 20040309 US 2001-831082 20010913
 HK 1040078 A1 20040709 HK 2002-101470 20020226
 PRAI JP 1998-324026 A 19981113
 WO 1999-JP6296 W 19991111
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 22 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 132:334464 CA
 TI Preparation of benzimidazole and indole derivatives and remedies for polycystic ovary syndrome containing them
 IN Hirosumi, Jiro; Mutoh, Seitaro; Yamasaki, Noritsugu; Imoto, Takafumi
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; Daicel Chemical Industries, Ltd.
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000028991	A1	20000525	WO 1999-JP6267	19991110
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1132087	A1	20010912	EP 1999-972100	19991110
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	HU 200104029	A2	20020529	HU 2001-4029	19991111
	CN 1136195	B	20040128	CN 1999-814325	19991111
PRAI	JP 1998-324026	A	19981113		
	WO 1999-JP6267	W	19991110		
OS	MARPAT 132:334464				

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 23 OF 23 CA COPYRIGHT 2007 ACS on STN

Full Text

AN 127:135799 CA
 TI Preparation of benzimidazole derivatives as drugs
 IN Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Oku, Teruo; Sawada, Kouzou
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 380 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724334	A1	19970710	WO 1996-JP3858	19961227
	W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2241186	A1	19970628	CA 1996-2241186	19961227
	CA 2241186	C	20060214		
	AU 9712095	A	19970728	AU 1997-12095	19961227
	AU 722514	B2	20000803		
	EP 882718	A1	19981209	EP 1996-943331	19961227
	EP 882718	B1	20050831		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1211238	A	19990317	CN 1996-180137	19961227
	HU 9900625	A2	19990628	HU 1999-625	19961227
	HU 9900625	A3	20030428		
	BR 9612434	A	19991228	BR 1996-12434	19961227
	JP 2000159749	A	20000613	JP 2000-8395	19961227
	JP 3063162	B2	20000712	JP 1997-524201	19961227
	NZ 324834	A	20011130	NZ 1996-324834	19961227
	IL 124969	A	20020912	IL 1996-124969	19961227
	AT 303365	T	20050915	AT 1996-943331	19961227
	ES 2244979	T3	20051216	ES 1996-943331	19961227

ZA 9610918	A	19970708	ZA 1996-10918	19961230
TW 548272	B	20030821	TW 1997-86100149	19970108
ZA 9708998	A	19980420	ZA 1997-8998	19971008
US 6166219	A	20001226	US 1998-91997	19981102
US 6352985	B1	20020305	US 2000-492955	20000128
PRAI JP 1995-343425	A	19951228		
JP 1996-287676	A	19961008		
JP 1997-524201	A	19961227		
WO 1996-JP3858	W	19961227		
US 1998-91997	A1	19981102		
OS MARPAT 127:135799				

=> file uspatall
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
67.78	131.57

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 19:30:17 ON 08 JUN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:30:17 ON 08 JUN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> e kawasugi k/in

E1	6	KAWASOME TOSHIKI/IN
E2	1	KAWASUE KIKUHI/IN
E3	0 -->	KAWASUGI K/IN
E4	1	KAWASUGI KANAME/IN
E5	3	KAWASUGI KAZUHIRO/IN
E6	1	KAWASUGI KENJI/IN
E7	1	KAWASUGI MASAHIRO/IN
E8	1	KAWASUGI MASASHI/IN
E9	2	KAWASUGI NAOKI/IN
E10	7	KAWASUGI TADAAKI/IN
E11	1	KAWASUJI KEIJI/IN
E12	3	KAWASUJI TAKASHI/IN

=> s e4

L40 1 "KAWASUGI KANAME"/IN

=> d

L40 ANSWER 1 OF 1 USPATFULL on STN

Full Text

AN 2007:121704 USPATFULL
TI Medicinal composition
IN **Kawasugi, Kaname, Tokyo, JAPAN**
PI US 2007105910 A1 20070510
AI US 2003-572557 A1 20030917 (10)
WO 2003-JP11847 20030917
20060317 PCT 371 date
DT Utility
FS APPLICATION
LN.CNT 244
INCL INCLM: 514/342.000
INCLS: 514/369.000; 514/350.000
NCL NCLM: 514/342.000
NCLS: 514/369.000; 514/350.000
IC IPCI A61K0031-4439 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4415 [I,A];
A61K0031-426 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

E VITAMIN B1/CN
L1 1 S E3
E PIOGLITAZONE/CN

L2 1 S E3
E ROSIGLITAZONE/CN
L3 1 S E3
E CS-011/CN
E CS 011/CN
L4 1 S E3
E TAK 559/CN
L5 1 S E3
E FK 614/CN
L6 1 S E3

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

L7 1 S L1
L8 1 S L2
L9 1 S L3
L10 0 S L4
L11 0 S L5
L12 0 S L6

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

L13 7457 S L1
L14 12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15 13000 S L13 OR L14
L16 1041 S L2
L17 1426 S PIOGLITAZONE
L18 1426 S L16 OR L17
L19 1361 S L3
L20 1891 S ROSIGLITAZONE
L21 1891 S L19 OR L20
L22 0 S CS-011
L23 5 S (TAK-559 OR FK-614)
L24 0 S L15 AND L18
L25 0 S L14 AND L21
L26 0 S L14 AND L23
L27 286036 S DIABET?
L28 0 S L15 AND L21
L29 317 S L15 AND L27

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

L30 1975 S L3
L31 9 S L4
L32 19 S L5
L33 23 S L6
L34 23452 S L1
L35 1 S L31 AND L34
L36 1 S L32 AND L34
L37 1 S L33 AND L34
L38 133460 S DIABET?/AB, BI
L39 355 S L34 AND L38

FILE 'USPATFULL, USPAT2' ENTERED AT 19:30:17 ON 08 JUN 2007
E KAWASUGI K/IN

L40 1 S E4

=> s l1

L41 1017 L1

=> s (vitamin b1 or thiamine or thiamin)

L42 14147 (VITAMIN B1 OR THIAMINE OR THIAMIN)

=> s diabet?

L43 81684 DIABET?

=> s l41 or l42

L44 14292 L41 OR L42

=> s l43 and l44

L45 2842 L43 AND L44

=> s (vitamin b1 or thiamine or thiamin)/clm

L46 1132 (VITAMIN B1 OR THIAMINE OR THIAMIN)/CLM

=> s diabet?/clm
L47 15924 DIABET?/CLM

=> s 146 and 147
L48 61 L46 AND L47

=> d 1-61

L48 ANSWER 1 OF 61 USPATFULL on STN

Full Text

AN 2007:100100 USPATFULL
TI Methods and compositions for generating bioactive assemblies of increased complexity and uses
IN Chang, Chien Hsing, Downingtown, PA, UNITED STATES
Goldenberg, David M., Mendham, NJ, UNITED STATES
McBride, William J., Boonton, NJ, UNITED STATES
Rossi, Edmund A., Nutley, NJ, UNITED STATES
PA IBC PHARMACEUTICALS, INC. (U.S. corporation)
PI US 2007086942 A1 20070419
AI US 2006-478021 A1 20060629 (11)
RLI Continuation-in-part of Ser. No. US 2006-389358, filed on 24 Mar 2006, PENDING Continuation-in-part of Ser. No. US 2006-391584, filed on 28 Mar 2006, PENDING
PRAI WO 2006-US10762 20060324
WO 2006-US12084 20060329
US 2006-782332P 20060314 (60)
US 2005-728292P 20051019 (60)
US 2005-751196P 20051216 (60)
DT Utility
FS APPLICATION
LN.CNT 2657
INCL INCLM: 424/001.490
INCLS: 435/006.000; 435/007.100; 435/287.200; 530/391.100; 435/007.320; 530/351.000; 530/350.000; 435/189.000; 435/188.500
NCL NCLM: 424/001.490
NCLS: 435/006.000; 435/007.100; 435/007.320; 435/188.500; 435/189.000; 435/287.200; 530/350.000; 530/351.000; 530/391.100
IC IPCI A61K0051-00 [I,A]; C12Q0001-68 [I,A]; G01N0033-53 [I,A]; G01N0033-554 [I,A]; C07K0016-46 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 2 OF 61 USPATFULL on STN

Full Text

AN 2007:75106 USPATFULL
TI Nutritional supplements
IN Woods, Cindy J.P., San Francisco, CA, UNITED STATES
PI US 2007065456 A1 20070322
AI US 2006-522830 A1 20060918 (11)
PRAI US 2005-718888P 20050920 (60)
DT Utility
FS APPLICATION
LN.CNT 1185
INCL INCLM: 424/195.170
INCLS: 424/725.000; 424/764.000; 424/738.000; 514/002.000; 514/054.000; 514/440.000; 514/554.000; 514/562.000; 514/729.000; 424/641.000; 424/702.000; 424/639.000; 514/356.000; 514/688.000; 424/761.000; 424/735.000; 424/745.000; 424/754.000; 424/750.000; 424/768.000; 514/250.000; 424/756.000; 514/276.000; 514/393.000; 424/705.000; 514/563.000
NCL NCLM: 424/195.170
NCLS: 424/639.000; 424/641.000; 424/702.000; 424/705.000; 424/725.000; 424/735.000; 424/738.000; 424/745.000; 424/750.000; 424/754.000; 424/756.000; 424/761.000; 424/764.000; 424/768.000; 514/002.000; 514/054.000; 514/250.000; 514/276.000; 514/356.000; 514/393.000; 514/440.000; 514/554.000; 514/562.000; 514/563.000; 514/688.000; 514/729.000
IC IPCI A61K0038-48 [I,A]; A61K0038-43 [I,C*]; A61K0036-8962 [I,A]; A61K0036-88 [I,C*]; A61K0036-55 [I,A]; A61K0036-28 [I,A]; A61K0036-185 [I,C*]; A61K0031-045 [I,A]; A61K0033-04 [I,A]; A61K0033-32 [I,A]; A61K0031-205 [I,A]; A61K0031-185 [I,C*]; A61K0031-385 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 3 OF 61 USPATFULL on STN

Full Text

AN 2007:55355 USPATFULL
TI Methods and compositions for the treatment of diseases characterized by
calcification and/or plaque formation
IN Kajander, E. Olavi, Lakeland, FL, UNITED STATES
Aho, K., Kuopio, FINLAND
Ciftcioglu, Neva, Houston, TX, UNITED STATES
Millican, H.B., Lakeland, FL, UNITED STATES
Maniscalco, B., Tampa, FL, UNITED STATES
PA Nanobac Pharmaceuticals, Inc. (U.S. corporation)
PI US 2007048296 A1 20070301
AI US 2006-544048 A1 20061006 (11)
RLI Continuation of Ser. No. US 2005-182076, filed on 15 Jul 2005, PENDING
PRAI US 2004-587871P 20040715 (60)
DT Utility
FS APPLICATION
LN.CNT 1305
INCL INCLM: 424/094.100
INCLS: 424/702.000; 424/765.000; 424/766.000; 424/094.660; 514/251.000;
514/454.000; 514/350.000; 514/356.000; 514/566.000; 514/565.000
NCL NCLM: 424/094.100
NCLS: 424/094.660; 424/702.000; 424/765.000; 424/766.000; 514/251.000;
514/350.000; 514/356.000; 514/454.000; 514/565.000; 514/566.000
IC IPCI A61K0038-46 [I,A]; A61K0038-43 [I,A]; A61K0031-525 [I,A];
A61K0031-519 [I,C*]; A61K0033-04 [I,A]; A61K0036-73 [I,A];
A61K0036-87 [I,A]; A61K0036-185 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 4 OF 61 USPATFULL on STN

Full Text

AN 2007:49228 USPATFULL
TI Enzyme cofactor combination for supplementing pyruvate dehydrogenase and
alpha ketoglutarate dehydrogenase complexes
IN Howard, James R., Brawley, CA, UNITED STATES
PI US 2007043054 A1 20070222
AI US 2005-562522 A1 20050315 (10)
WO 2005-US8439 20050315
20060630 PCT 371 date
PRAI US 2004-553168P 20040315 (60)
DT Utility
FS APPLICATION
LN.CNT 659
INCL INCLM: 514/250.000
INCLS: 514/276.000; 514/356.000; 514/561.000
NCL NCLM: 514/250.000
NCLS: 514/276.000; 514/356.000; 514/561.000
IC IPCI A61K0031-51 [I,A]; A61K0031-506 [I,C*]; A61K0031-455 [I,A];
A61K0031-198 [I,A]; A61K0031-185 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 5 OF 61 USPATFULL on STN

Full Text

AN 2007:24337 USPATFULL
TI Nitric oxide donors and uses thereof
IN Assaf, Peter, Kfar-Miilya, ISRAEL
Gazaleen-Mariee, Elham, Yaffia, ISRAEL
Naveh, Michael, Ramat-HaSharon, ISRAEL
PA Renopharm Ltd., Nazareth, ISRAEL, 16000 (non-U.S. corporation)
PI US 2007021382 A1 20070125
AI US 2005-555664 A1 20050505 (10)
WO 2005-IL481 20050505
20051104 PCT 371 date
PRAI US 2004-567824P 20040505 (60)
US 2005-651619P 20050211 (60)
DT Utility
FS APPLICATION
LN.CNT 4742
INCL INCLM: 514/063.000
INCLS: 514/064.000; 514/150.000; 514/365.000; 514/092.000; 514/369.000;
514/370.000

NCL NCLM: 514/063.000
NCLS: 514/064.000; 514/092.000; 514/150.000; 514/365.000; 514/369.000;
514/370.000
IC IPCI A61K0031-695 [I,A]; A61K0031-69 [I,A]; A61K0031-655 [I,A];
A61K0031-426 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 6 OF 61 USPATFULL on STN

Full Text

AN 2007:17153 USPATFULL
TI Composition for improving the efficacy and reducing the side effects of
omega 3 fatty acids, fish oils and cardiovascular and diabetic
treatments
IN Hendrix, Curt, Encino, CA, UNITED STATES
PI US 2007014866 A1 20070118
AI US 2006-484230 A1 20060710 (11)
PRAI US 2005-699669P 20050715 (60)
DT Utility
FS APPLICATION
LN.CNT 163
INCL INCLM: 424/523.000
INCLS: 514/547.000; 514/089.000; 514/025.000; 514/423.000; 514/460.000;
514/458.000; 514/554.000; 514/561.000; 514/690.000; 514/682.000
NCL NCLM: 424/523.000
NCLS: 514/025.000; 514/089.000; 514/423.000; 514/458.000; 514/460.000;
514/547.000; 514/554.000; 514/561.000; 514/682.000; 514/690.000
IC IPCI A61K0035-60 [I,A]; A61K0035-56 [I,C*]; A61K0031-7034 [I,A];
A61K0031-7028 [I,C*]; A61K0031-675 [I,A]; A61K0031-355 [I,A];
A61K0031-352 [I,C*]; A61K0031-366 [I,A]; A61K0031-22 [I,A];
A61K0031-21 [I,C*]; A61K0031-205 [I,A]; A61K0031-195 [I,A];
A61K0031-185 [I,C*]; A61K0031-12 [I,A]; A61K0031-401 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 7 OF 61 USPATFULL on STN

Full Text

AN 2006:334752 USPATFULL
TI Pyridoxamine for the treatment of diabetic kidney disease
IN Degenhardt, Thorsten, Durham, NC, UNITED STATES
Schotzinger, Robert, Morrisville, NC, UNITED STATES
Fox, Wesley J., Cary, NC, UNITED STATES
PA BioStratum, Inc. (U.S. corporation)
PI US 2006287367 A1 20061221
AI US 2006-513530 A1 20060831 (11)
RLI Continuation of Ser. No. US 2004-871224, filed on 18 Jun 2004, PENDING
PRAI US 2003-480032P 20030620 (60)
US 2004-562062P 20040414 (60)
DT Utility
FS APPLICATION
LN.CNT 589
INCL INCLM: 514/350.000
INCLS: 514/003.000; 514/355.000; 514/592.000; 514/423.000; 514/460.000;
514/548.000; 514/571.000
NCL NCLM: 514/350.000
NCLS: 514/003.000; 514/355.000; 514/423.000; 514/460.000; 514/548.000;
514/571.000; 514/592.000
IC IPCI A61K0031-4415 [I,A]; A61K0038-28 [I,A]; A61K0031-401 [I,A];
A61K0031-366 [I,A]; A61K0031-22 [I,A]; A61K0031-21 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 8 OF 61 USPATFULL on STN

Full Text

AN 2006:315842 USPATFULL
TI Nutraceuticals for the treatment of neuropathy
IN Vinik, Aaron I., Norfolk, VA, UNITED STATES
Jacot, Jorge L., Virginia Beach, VA, UNITED STATES
PA Eastern Virginia Medical School, Norfolk, VA, UNITED STATES (U.S.
corporation)
PI US 2006270625 A1 20061130
AI US 2006-431830 A1 20060511 (11)
PRAI US 2005-680521P 20050513 (60)
DT Utility
FS APPLICATION

LN.CNT 736
 INCL INCLM: 514/052.000
 INCLS: 514/251.000; 514/547.000; 514/440.000; 514/276.000; 514/350.000;
 514/356.000; 514/458.000; 514/474.000
 NCL NCLM: 514/052.000
 NCLS: 514/251.000; 514/276.000; 514/350.000; 514/356.000; 514/440.000;
 514/458.000; 514/474.000; 514/547.000
 IC IPCI A61K0031-714 [I,A]; A61K0031-7135 [I,C*]; A61K0031-375 [I,A];
 A61K0031-4415 [I,A]; A61K0031-455 [I,A]; A61K0031-525 [I,A];
 A61K0031-519 [I,C*]; A61K0031-51 [I,A]; A61K0031-506 [I,C*];
 A61K0031-385 [I,A]; A61K0031-355 [I,A]; A61K0031-352 [I,C*];
 A61K0031-22 [I,A]; A61K0031-21 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 9 OF 61 USPATFULL on STN

Full Text

AN 2006:314752 USPATFULL
 TI Metallo-lactoferrin-coenzyme compositions for trigger and release of
 bioenergy
 IN Naidu, A. Satyanarayan, Diamond Bar, CA, UNITED STATES
 Naidu, A.G. Tezus, Diamond Bar, CA, UNITED STATES
 Naidu, A.G. Sreus, Diamond Bar, CA, UNITED STATES
 PI US 2006269535 A1 20061130
 AI US 2006-442473 A1 20060526 (11)
 PRAI US 2005-686257P 20050531 (60)
 DT Utility
 FS APPLICATION

LN.CNT 1595

INCL INCLM: 424/094.100
 INCLS: 514/006.000; 514/054.000
 NCL NCLM: 424/094.100
 NCLS: 514/006.000; 514/054.000
 IC IPCI A61K0038-43 [I,A]; A61K0038-40 [I,A]; A61K0031-715 [I,A];
 A61K0031-737 [I,A]; A61K0031-718 [I,A]; A61K0031-716 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 10 OF 61 USPATFULL on STN

Full Text

AN 2006:301147 USPATFULL
 TI A COMBINATION OF MITOCHONDRIAL NUTRIENTS FOR RELIEVING STRESS,
 PREVENTING AND IMPROVING STRESS-RELATED DISORDERS
 IN Liu, Jiankang, 43 Rock Lane, Berkeley,, CA, UNITED STATES 94708
 PA Liu, Jiankang, Berkeley, CA, UNITED STATES (U.S. corporation)
 PI US 2006257502 A1 20061116
 AI US 2005-908425 A1 20050511 (10)
 DT Utility
 FS APPLICATION

LN.CNT 1428

INCL INCLM: 424/682.000
 INCLS: 514/171.000; 514/052.000; 514/251.000; 514/350.000; 514/355.000;
 514/562.000; 514/078.000; 514/440.000; 514/458.000; 514/474.000;
 514/546.000; 514/561.000; 514/699.000; 514/419.000; 514/276.000;
 514/725.000
 NCL NCLM: 424/682.000
 NCLS: 514/052.000; 514/078.000; 514/171.000; 514/251.000; 514/276.000;
 514/350.000; 514/355.000; 514/419.000; 514/440.000; 514/458.000;
 514/474.000; 514/546.000; 514/561.000; 514/562.000; 514/699.000;
 514/725.000
 IC IPCI A61K0033-06 [I,A]; A61K0031-573 [I,A]; A61K0031-57 [I,C*];
 A61K0031-714 [I,A]; A61K0031-7135 [I,C*]; A61K0031-685 [I,A];
 A61K0031-683 [I,C*]; A61K0031-525 [I,A]; A61K0031-519 [I,C*];
 A61K0031-51 [I,A]; A61K0031-506 [I,C*]; A61K0031-4415 [I,A];
 A61K0031-198 [I,A]; A61K0031-185 [I,C*]; A61K0031-385 [I,A];
 A61K0031-355 [I,A]; A61K0031-352 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 11 OF 61 USPATFULL on STN

Full Text

AN 2006:267676 USPATFULL
 TI Methods for generating stably linked complexes composed of homodimers,
 homotetramers or dimers of dimers and uses
 IN Chang, Chien Hsing, Downingtown, PA, UNITED STATES

Goldenberg, David M., Mendham, NJ, UNITED STATES
 McBride, William J., Boonton, NJ, UNITED STATES
 Rossi, Edmund A., Nutley, NJ, UNITED STATES
 PA IBC PHARMACEUTICALS, INC. (U.S. corporation)
 PI US 2006228357 A1 20061012
 AI US 2006-389358 A1 20060324 (11)
 PRAI US 2005-668603P 20050406 (60)
 US 2005-728292P 20051019 (60)
 US 2005-751196P 20051216 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3102
 INCL INCLM: 424/144.100
 INCLS: 530/350.000; 530/370.000; 530/409.000; 530/391.100; 424/178.100;
 424/184.100; 435/005.000; 435/007.230; 977/906.000
 NCL NCLM: 424/144.100
 NCLS: 424/178.100; 424/184.100; 435/005.000; 435/007.230; 530/350.000;
 530/370.000; 530/391.100; 530/409.000; 977/906.000
 IC IPCI C12Q0001-70 [I,A]; G01N0033-574 [I,A]; A61K0039-395 [I,A];
 C07K0014-82 [I,A]; C07K0016-30 [I,A]; C07K0016-18 [I,C*];
 C07K0014-415 [I,A]; A61K0039-00 [I,A]; C07K0016-46 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 12 OF 61 USPATFULL on STN

Full Text

AN 2006:261158 USPATFULL
 TI Dermatological compositions and salts for the treatment of
 dermatological diseases
 IN Weidner, Morten Sloth, Virum, DENMARK
 PA Astion Development A/S (non-U.S. corporation)
 PI US 2006222671 A1 20061005
 AI US 2006-392938 A1 20060330 (11)
 PRAI DK 2005-437 20050330
 DK 2005-438 20050330
 DK 2005-949 20050627
 DK 2005-948 20050627
 US 2005-694774P 20050627 (60)
 US 2005-695040P 20050628 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2344
 INCL INCLM: 424/401.000
 INCLS: 514/374.000; 514/365.000
 NCL NCLM: 424/401.000
 NCLS: 514/365.000; 514/374.000
 IC IPCI A61K0031-426 [I,A]; A61K0031-421 [I,A]; A61K0031-49 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 13 OF 61 USPATFULL on STN

Full Text

AN 2006:118318 USPATFULL
 TI Pharmaceutically active oligosaccharide conjugates
 IN Orlando, Michele, Giessen, GERMANY, FEDERAL REPUBLIC OF
 Hemberger, Jurgen, Aschaffenburg, GERMANY, FEDERAL REPUBLIC OF
 Delbos-Krampe, Jeanne, Marburg, GERMANY, FEDERAL REPUBLIC OF
 PI US 2006100163 A1 20060511
 AI US 2003-530849 A1 20031008 (10)
 WO 2003-EP11129 20031008
 20060119 PCT 371 date
 PRAI DE 2002-20215415 20021008
 EP 2003-8177 20030408
 DT Utility
 FS APPLICATION
 LN.CNT 1244
 INCL INCLM: 514/025.000
 INCLS: 514/034.000; 514/054.000; 536/006.400; 536/017.400; 536/053.000
 NCL NCLM: 514/025.000
 NCLS: 514/034.000; 514/054.000; 536/006.400; 536/017.400; 536/053.000
 IC IPCI A61K0031-704 [I,A]; A61K0031-7028 [I,C*]; A61K0031-70 [I,A];
 C07H0015-24 [I,A]; C07H0015-00 [I,C*]; A61K0031-715 [I,A]
 IPCR A61K0031-7028 [I,C]; A61K0031-704 [I,A]; A61K0031-70 [I,C];
 A61K0031-70 [I,A]; A61K0031-715 [I,C]; A61K0031-715 [I,A];

A61K0047-48 [I,C*]; A61K0047-48 [I,A]; C07H0015-00 [I,C];
C07H0015-24 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 14 OF 61 USPATFULL on STN

Full Text

AN 2006:110649 USPATFULL
TI Methods for reducing cholesterol using Bacillus coagulans spores,
systems and compositions
IN Farmer, Scan, La Jolla, CA, UNITED STATES
Lefkowitz, Andrew R., Cleveland, OH, UNITED STATES
PI US 2006093591 A1 20060504
AI US 2004-978726 A1 20041101 (10)
DT Utility
FS APPLICATION
LN.CNT 946
INCL INCLM: 424/093.450
NCL NCLM: 424/093.450
IC IPCI A61K0035-74 [I,A]; A61K0035-66 [I,C*]
IPCR A61K0035-66 [I,C]; A61K0035-74 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 15 OF 61 USPATFULL on STN

Full Text

AN 2006:98561 USPATFULL
TI Methods and compositions for the treatment of diseases characterized by
calcification and/or plaque formation
IN Kajander, E. Olavi, Lakeland, FL, UNITED STATES
Aho, K., Kuopio, FINLAND
Ciftcioglu, Neva, Houston, TX, UNITED STATES
Millican, H.B., Lakeland, FL, UNITED STATES
Maniscalco, B., Tampa, FL, UNITED STATES
PA Nanobac Pharmaceuticals, Inc. (U.S. corporation)
PI US 2006083727 A1 20060420
AI US 2005-182076 A1 20050715 (11)
PRAI US 2004-587871P 20040715 (60)
DT Utility
FS APPLICATION
LN.CNT 1304
INCL INCLM: 424/094.100
INCLS: 424/094.200; 424/765.000; 424/766.000; 514/154.000; 514/566.000;
514/052.000; 514/251.000; 514/276.000; 514/350.000; 514/356.000;
514/565.000; 514/564.000; 424/702.000
NCL NCLM: 424/094.100
NCLS: 424/094.200; 424/702.000; 424/765.000; 424/766.000; 514/052.000;
514/154.000; 514/251.000; 514/276.000; 514/350.000; 514/356.000;
514/564.000; 514/565.000; 514/566.000
IC IPCI A61K0038-54 [I,A]; A61K0038-43 [I,A]; A61K0036-87 [I,A];
A61K0036-734 [I,A]; A61K0036-185 [I,C*]; A61K0031-525 [I,A];
A61K0031-519 [I,C*]; A61K0031-65 [I,A]; A61K0031-714 [I,A];
A61K0031-7135 [I,C*]; A61K0031-198 [I,A]; A61K0031-185 [I,C*];
A61K0031-455 [I,A]; A61K0031-4415 [I,A]
IPCR A61K0038-43 [I,C]; A61K0038-54 [I,A]; A61K0031-185 [I,C];
A61K0031-198 [I,A]; A61K0031-4415 [I,C]; A61K0031-4415 [I,A];
A61K0031-455 [I,C]; A61K0031-455 [I,A]; A61K0031-519 [I,C];
A61K0031-525 [I,A]; A61K0031-65 [I,C]; A61K0031-65 [I,A];
A61K0031-7135 [I,C]; A61K0031-714 [I,A]; A61K0036-185 [I,C];
A61K0036-734 [I,A]; A61K0036-87 [I,A]; A61K0038-43 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 16 OF 61 USPATFULL on STN

Full Text

AN 2006:73816 USPATFULL
TI Composition and method to optimize and customize nutritional supplement
formulations by measuring genetic and metabolomic contributing factors
to disease diagnosis, stratification, prognosis, metabolism, and
therapeutic outcomes
IN Blum, Kenneth, San Antonio, TX, UNITED STATES
Meshkin, Brian, Temecula, CA, UNITED STATES
Downs, Bernard William, Lederach, PA, UNITED STATES
PI US 2006062859 A1 20060323
AI US 2005-197980 A1 20050805 (11)

PRAI US 2004-599829P 20040805 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6858
 INCL INCLM: 424/725.000
 INCLS: 424/765.000; 424/769.000; 435/006.000; 514/002.000; 514/054.000;
 514/171.000
 NCL NCLM: 424/725.000
 NCLS: 424/765.000; 424/769.000; 435/006.000; 514/002.000; 514/054.000;
 514/171.000
 IC IPCI A61K0036-30 [I,A]; A61K0036-185 [I,C*]; A61K0038-38 [I,A];
 A61K0031-737 [I,A]; A61K0031-56 [I,A]
 IPCR A61K0036-185 [I,C]; A61K0036-30 [I,A]; A61K0031-56 [I,C];
 A61K0031-56 [I,A]; A61K0031-737 [I,C]; A61K0031-737 [I,A];
 A61K0038-38 [I,C]; A61K0038-38 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 17 OF 61 USPATFULL on STN

Full Text

AN 2006:27538 USPATFULL
 TI Controlled release alpha lipoic acid formulation with an inositol
 compound
 IN Byrd, Edward A., San Francisco, CA, UNITED STATES
 PI US 2006024367 A1 20060202
 AI US 2005-199919 A1 20050808 (11)
 RLI Continuation-in-part of Ser. No. US 2003-412559, filed on 11 Apr 2003,
 PENDING Continuation of Ser. No. US 2001-755890, filed on 5 Jan 2001,
 GRANTED, Pat. No. US 6572888 Continuation-in-part of Ser. No. US
 1999-288245, filed on 8 Apr 1999, GRANTED, Pat. No. US 6197340
 Continuation-in-part of Ser. No. US 1998-112623, filed on 9 Jul 1998,
 ABANDONED
 PRAI US 1998-102605P 19981001 (60)
 US 1998-87203P 19980528 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2429
 INCL INCLM: 424/468.000
 INCLS: 514/025.000; 514/102.000; 514/440.000
 NCL NCLM: 424/468.000
 NCLS: 514/025.000; 514/102.000; 514/440.000
 IC IPCI A61K0009-22 [I,A]; A61K0031-704 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-663 [I,A]; A61K0031-662 [I,C*]; A61K0031-385 [I,A]
 IPCR A61K0009-22 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
 A61K0009-22 [I,C]; A61K0009-50 [N,C*]; A61K0009-50 [N,A];
 A61K0031-185 [I,C*]; A61K0031-197 [I,A]; A61K0031-385 [I,C];
 A61K0031-385 [I,A]; A61K0031-425 [I,C*]; A61K0031-425 [I,A];
 A61K0031-506 [I,C*]; A61K0031-51 [I,A]; A61K0031-64 [I,C*];
 A61K0031-64 [I,A]; A61K0031-662 [I,C]; A61K0031-663 [I,A];
 A61K0031-7028 [I,C]; A61K0031-704 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 18 OF 61 USPATFULL on STN

Full Text

AN 2005:293482 USPATFULL
 TI Composition for relieving discomfort
 IN Hageman, Robert Johan Joseph, Waddinxveen, NETHERLANDS
 Bindels, Jacob Geert, Zoetermeer, NETHERLANDS
 PI US 2005256031 A1 20051117
 AI US 2005-125201 A1 20050510 (11)
 RLI Continuation-in-part of Ser. No. US 2001-889793, filed on 24 Oct 2001,
 GRANTED, Pat. No. US 6900180 A 371 of International Ser. No. WO
 2000-NL42, filed on 20 Jan 2000
 PRAI EP 1999-200166 19990120
 EP 1999-201359 19990429
 DT Utility
 FS APPLICATION
 LN.CNT 899
 INCL INCLM: 514/002.000
 INCLS: 514/052.000; 514/054.000; 514/251.000; 514/276.000; 514/350.000;
 514/356.000; 514/554.000; 514/553.000; 514/562.000
 NCL NCLM: 514/002.000
 NCLS: 514/052.000; 514/054.000; 514/251.000; 514/276.000; 514/350.000;

514/356.000; 514/553.000; 514/554.000; 514/562.000

IC [7]

ICM A61K038-16

ICS A61K031-714; A61K031-715; A61K031-455; A61K031-4415; A61K031-525

IPCI A61K0038-16 [ICM,7]; A61K0031-714 [ICS,7]; A61K0031-7135 [ICS,7,C*]; A61K0031-715 [ICS,7]; A61K0031-455 [ICS,7]; A61K0031-4415 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519 [ICS,7,C*]

IPCR C07D0475-00 [I,C*]; C07D0475-04 [I,A]; A23L0001-29 [I,C*]; A23L0001-29 [I,A]; A23L0001-302 [I,C*]; A23L0001-302 [I,A]; A23L0001-304 [I,C*]; A23L0001-304 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-14 [I,C*]; A61K0031-14 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61K0031-403 [I,C*]; A61K0031-405 [I,A]; A61K0031-409 [I,C*]; A61K0031-409 [I,A]; A61K0031-4415 [I,C*]; A61K0031-4415 [I,A]; A61K0031-506 [I,C*]; A61K0031-51 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7076 [I,A]; A61K0031-7135 [I,C*]; A61K0031-714 [I,A]; A61K0033-06 [I,C*]; A61K0033-06 [I,A]; A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61P0003-00 [I,C*]; A61P0003-02 [I,A]; A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-22 [I,A]; C07D0209-00 [I,C*]; C07D0209-20 [I,A]; C07D0213-00 [I,C*]; C07D0213-67 [I,A]; C07D0417-00 [I,C*]; C07D0417-06 [I,A]; C07H0019-00 [I,C*]; C07H0019-167 [I,A]; C07H0023-00 [I,C*]; C07H0023-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 19 OF 61 USPATFULL on STN

Full Text

AN 2005:275877 USPATFULL

TI System and method of individualized mass diagnosis and treatment of obesity

IN Wooten, Richard, Tigard, OR, UNITED STATES
Libke, Al, Ketchum, ID, UNITED STATES

PI US 2005240444 A1 20051027

AI US 2004-832731 A1 20040426 (10)

DT Utility

FS APPLICATION

LN.CNT 2710

INCL INCLM: 705/003.000

NCL NCLM: 705/003.000

IC [7]

ICM G06F017-60

IPCI G06F0017-60 [ICM,7]

IPCR G06Q0030-00 [I,C*]; G06Q0030-00 [I,A]

L48 ANSWER 20 OF 61 USPATFULL on STN

Full Text

AN 2005:274587 USPATFULL

TI Immunocapture-based measurements of mammalian pyruvate dehydrogenase complex

IN Capaldi, Roderick A., Eugene, OR, UNITED STATES
Lib, Margarita, Springfield, OR, UNITED STATES
Marusich, Michael F., Eugene, OR, UNITED STATES

PI US 2005239143 A1 20051027

AI US 2003-526325 A1 20030829 (10)
WO 2003-US27306 20030829
20050228 PCT 371 date

PRAI US 2002-60407376 20020830

DT Utility

FS APPLICATION

LN.CNT 1383

INCL INCLM: 435/007.200

NCL NCLM: 435/007.200

IC [7]

ICM G01N033-53

ICS G01N033-567

IPCI G01N0033-53 [ICM,7]; G01N0033-567 [ICS,7]

IPCR G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-567 [I,C*]; G01N0033-567 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 21 OF 61 USPATFULL on STN

Full Text

AN 2005:209552 USPATFULL
TI Medicinal composition containing an HMG-CoA reductase inhibitor
IN Kondo, Tatsuhito, Tokyo, JAPAN
Takagi, Ikuo, Matsudo-shi, JAPAN
Nakayama, Masato, Kitakatsushika-gun, JAPAN
Torizumi, Yasuhiro, Ryugasaki-shi, JAPAN
PA SANKYO COMPANY, LIMITED, Tokyo, JAPAN (non-U.S. corporation)
PI US 2005182036 A1 20050818
AI US 2005-45400 A1 20050127 (11)
RLI Continuation-in-part of Ser. No. WO 2003-JP9835, filed on 1 Aug 2003,
UNKNOWN
PRAI JP 2002-225979 20020802
JP 2002-260719 20020906
DT Utility
FS APPLICATION
LN.CNT 781
INCL INCLM: 514/171.000
INCLS: 514/423.000; 514/460.000; 514/548.000; 514/276.000
NCL NCLM: 514/171.000
NCLS: 514/276.000; 514/423.000; 514/460.000; 514/548.000
IC [7]
ICM A61K031-56
ICS A61K031-51; A61K031-401; A61K031-366; A61K031-225
IPCI A61K0031-56 [ICM,7]; A61K0031-51 [ICS,7]; A61K0031-506
[ICS,7,C*]; A61K0031-401 [ICS,7]; A61K0031-366 [ICS,7];
A61K0031-225 [ICS,7]; A61K0031-21 [ICS,7,C*]
IPCR A61K0031-21 [I,C*]; A61K0031-225 [I,A]; A61K0031-365 [I,C*];
A61K0031-365 [I,A]; A61K0031-366 [I,C*]; A61K0031-366 [I,A];
A61K0031-40 [I,C*]; A61K0031-40 [I,A]; A61K0031-401 [I,C*];
A61K0031-401 [I,A]; A61K0031-506 [I,C*]; A61K0031-51 [I,A];
A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0031-575 [I,C*];
A61K0031-575 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 22 OF 61 USPATFULL on STN

Full Text

AN 2005:131904 USPATFULL
TI Benzoxazine and benzothiazine derivatives and pharmaceutical
compositions containing them
IN Bhuniya, Debnath, Hyderabad, INDIA
Das, Saibal Kumar, Hyderabad, INDIA
Madhavan, Gurram Ranga, Hyderabad, INDIA
Iqbal, Javed, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
PI US 2005113368 A1 20050526
AI US 2003-492454 A1 20021015 (10)
WO 2002-IB4275 20021015
PRAI IN 2001-84801 20011016
DT Utility
FS APPLICATION
LN.CNT 4879
INCL INCLM: 514/224.200
INCLS: 514/230.500; 544/105.000; 544/051.000
NCL NCLM: 514/224.200
NCLS: 514/230.500; 544/051.000; 544/105.000
IC [7]
ICM C07D279-16
ICS C07D265-36; A61K031-5415; A61K031-538
IPCI C07D0279-16 [ICM,7]; C07D0279-00 [ICM,7,C*]; C07D0265-36 [ICS,7];
C07D0265-00 [ICS,7,C*]; A61K0031-5415 [ICS,7]; A61K0031-538
[ICS,7]; A61K0031-5375 [ICS,7,C*]
IPCR A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61K0009-10 [I,C*];
A61K0009-10 [I,A]; A61K0009-14 [I,C*]; A61K0009-14 [I,A];
A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-48 [I,C*];
A61K0009-48 [I,A]; A61K0031-5375 [I,C*]; A61K0031-538 [I,A];
A61K0031-5415 [I,C*]; A61K0031-5415 [I,A]; A61P0001-00 [I,C*];
A61P0001-04 [I,A]; A61P0001-14 [I,A]; A61P0001-18 [I,A];
A61P0003-00 [I,C*]; A61P0003-04 [I,A]; A61P0003-06 [I,A];
A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
A61P0009-12 [I,A]; A61P0013-00 [I,C*]; A61P0013-12 [I,A];

A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0017-00 [I,C*];
A61P0017-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-10 [I,A];
A61P0021-00 [I,C*]; A61P0021-04 [I,A]; A61P0025-00 [I,C*];
A61P0025-28 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]; C07B0061-00 [I,C*]; C07B0061-00 [I,A];
C07C0227-00 [I,C*]; C07C0227-04 [I,A]; C07C0227-18 [I,A];
C07C0229-00 [I,C*]; C07C0229-34 [I,A]; C07C0229-42 [I,A];
C07D0265-00 [I,C*]; C07D0265-36 [I,A]; C07D0279-00 [I,C*];
C07D0279-16 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 23 OF 61 USPATFULL on STN

Full Text

AN 2005:112246 USPATFULL
TI Novel compounds and their use in medicine process for their preparation
and pharmaceutical compositions containing them
IN Das, Saibal Kumar, Hyderabad, Andhra Pradesh, INDIA
Bhuniya, Debnath, Hyderabad, Andhra Pradesh, INDIA
Madhavan, Gurram, Ranga, Hyderabad, Andhra Pradesh, INDIA
Iqbal, Javed, Hyderabad, Andhra Pradesh, INDIA
Chakrabarti, Ranjan, Hyderabad, Andhra Pradesh, INDIA
PI US 2005096331 A1 20050505
AI US 2003-499852 A1 20021217 (10)
WO 2002-IB5442 20021217
PRAI IN 2001-10292001 20011221
DT Utility
FS APPLICATION
LN.CNT 4722
INCL INCLM: 514/259.300
INCLS: 514/259.310; 544/280.000; 544/281.000
NCL NCLM: 514/259.300
NCLS: 514/259.310; 544/280.000; 544/281.000
IC [7]
ICM A61K031-519
ICS C07D487-04
IPCI A61K0031-519 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCR A61K0031-395 [I,C*]; A61K0031-395 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; A61P0003-00 [I,C*]; A61P0003-06 [I,A];
A61P0003-10 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
A61P0019-00 [I,C*]; A61P0019-10 [I,A]; A61P0029-00 [I,C*];
A61P0029-02 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
C07D0231-00 [I,C*]; C07D0231-40 [I,A]; C07D0473-00 [I,C*];
C07D0473-00 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 24 OF 61 USPATFULL on STN

Full Text

AN 2005:17397 USPATFULL
TI Pyridoxamine for the treatment of diabetic kidney disease
IN Degenhardt, Thorsten, Durham, NC, UNITED STATES
Schotzinger, Robert, Morrisville, NC, UNITED STATES
Fox, Wesley J., Cary, NC, UNITED STATES
PA BioStratum, Inc. (U.S. corporation)
PI US 2005014799 A1 20050120
AI US 2004-871224 A1 20040618 (10)
PRAI US 2003-480032P 20030620 (60)
US 2004-562062P 20040414 (60)
DT Utility
FS APPLICATION
LN.CNT 596
INCL INCLM: 514/352.000
NCL NCLM: 514/352.000
IC [7]
ICM A61K031-44
IPCI A61K0031-44 [ICM,7]
IPCR A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C*];
A61K0031-4412 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 25 OF 61 USPATFULL on STN

Full Text

AN 2004:328070 USPATFULL
 TI Oral formulation of lipid soluble thiamine and lipoic acid
 IN Byrd, Edward A., San Francisco, CA, UNITED STATES
 PA Medical Research Institute (U.S. corporation)
 PI US 2004259895 A1 20041223
 AI US 2003-693837 A1 20031023 (10)
 RLI Continuation-in-part of Ser. No. US 2003-412559, filed on 11 Apr 2003,
 PENDING Continuation of Ser. No. US 2001-755890, filed on 5 Jan 2001,
 GRANTED, Pat. No. US 6572888 Continuation-in-part of Ser. No. US
 1999-288245, filed on 8 Apr 1999, GRANTED, Pat. No. US 6197340
 Continuation-in-part of Ser. No. US 1998-112623, filed on 9 Jul 1998,
 ABANDONED
 PRAI US 1998-102605P 19981001 (60)
 US 1998-87203P 19980528 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2007
 INCL INCLM: 514/276.000
 INCLS: 514/440.000
 NCL NCLM: 514/276.000
 NCLS: 514/440.000
 IC [7]
 ICM A61K031-51
 ICS A61K031-385
 IPCI A61K0031-51 [ICM,7]; A61K0031-506 [ICM,7,C*]; A61K0031-385
 [ICS,7]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-50 [N,C*];
 A61K0009-50 [N,A]; A61K0031-185 [I,C*]; A61K0031-197 [I,A];
 A61K0031-385 [I,C*]; A61K0031-385 [I,A]; A61K0031-425 [I,C*];
 A61K0031-425 [I,A]; A61K0031-506 [I,C*]; A61K0031-51 [I,A];
 A61K0031-64 [I,C*]; A61K0031-64 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 26 OF 61 USPATFULL on STN

Full Text

AN 2004:326815 USPATFULL
 TI Composition for oral hygiene comprising a fluoride ion vector and an
 antioxidant
 IN Cazor, Jean-Louis, Saint Antoine, FRANCE
 Lhuisset, Francois, Gentilly, FRANCE
 Robineau, Pascale, Palaiseau, FRANCE
 PI US 2004258634 A1 20041223
 AI US 2004-481718 A1 20040722 (10)
 WO 2002-FR2313 20020703
 PRAI FR 2001-8852 20010704
 DT Utility
 FS APPLICATION
 LN.CNT 562
 INCL INCLM: 424/052.000
 NCL NCLM: 424/052.000
 IC [7]
 ICM A61K007-18
 IPCI A61K0007-18 [ICM,7]
 IPCR A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-23 [I,A];
 A61K0008-24 [I,A]; A61K0008-25 [I,A]; A61K0008-29 [I,A];
 A61K0008-30 [I,C*]; A61K0008-33 [I,A]; A61K0008-34 [I,A];
 A61K0008-37 [I,A]; A61K0008-44 [I,A]; A61K0008-67 [I,A];
 A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-68 [I,C*];
 A61K0009-68 [I,A]; A61P0039-00 [I,C*]; A61P0039-06 [I,A];
 A61Q0011-00 [I,C*]; A61Q0011-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 27 OF 61 USPATFULL on STN

Full Text

AN 2004:320669 USPATFULL
 TI Inhibitors of apoptosis of nerve cells
 IN Basic, Robert, Zagreb, CROATIA
 Slijepcevic, Milivoj, Zagreb, CROATIA
 Hadzija, Mirko, Zagreb, CROATIA
 Hadzija, Marijana, Zagreb, CROATIA
 PI US 2004253322 A1 20041216
 US 6953595 B2 20051011

AI US 2002-311392 A1 20021213 (10)
 WO 2001-HR19 20010504
 DT Utility
 FS APPLICATION
 LN.CNT 822
 INCL INCLM: 424/684.000
 INCLS: 424/773.000; 424/757.000; 514/052.000; 514/276.000; 514/251.000;
 514/350.000; 514/356.000
 NCL NCLM: 424/725.000; 424/684.000
 NCLS: 424/773.000; 424/774.000; 514/770.000; 424/757.000; 514/052.000;
 514/251.000; 514/276.000; 514/350.000; 514/356.000
 IC [7]
 ICM A61K035-78
 ICS A61K033-06; A61K031-525; A61K031-51
 IPCI A61K0035-78 [ICM,7]; A61K0033-06 [ICS,7]; A61K0031-525 [ICS,7];
 A61K0031-519 [ICS,7,C*]; A61K0031-51 [ICS,7]; A61K0031-506
 [ICS,7,C*]
 IPCI-2 A61K0035-78 [ICM,7]
 IPCR A61K0031-506 [I,C*]; A61K0031-51 [I,A]; A61K0031-519 [I,C*];
 A61K0031-525 [I,A]; A61K0033-06 [I,C*]; A61K0033-06 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*];
 A61P0003-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 28 OF 61 USPATFULL on STN

Full Text

AN 2004:314511 USPATFULL
 TI Method of identifying and treating insulin-resistant individuals who are
 responsive to anti-oxidant therapy
 IN Argyropoulos, George, Baton Rouge, LA, UNITED STATES
 Smith, Steven R., Baton Rouge, LA, UNITED STATES
 PI US 2004248183 A1 20041209
 AI US 2004-864622 A1 20040609 (10)
 PRAI US 2003-477158P 20030609 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 873
 INCL INCLM: 435/006.000
 NCL NCLM: 435/006.000
 IC [7]
 ICM C12Q001-68
 IPCI C12Q0001-68 [ICM,7]
 IPCR C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 29 OF 61 USPATFULL on STN

Full Text

AN 2004:216078 USPATFULL
 TI Sulfhydanthoins as phosphate isosteres
 IN Saunders, Jeffrey O., Acton, MA, UNITED STATES
 Miknis, Gregory F., Broomfield, CO, UNITED STATES
 Blake, James F., Longmont, CO, UNITED STATES
 PI US 2004167187 A1 20040826
 AI US 2003-749121 A1 20031230 (10)
 PRAI US 2002-437572P 20021230 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1302
 INCL INCLM: 514/362.000
 INCLS: 548/135.000
 NCL NCLM: 514/362.000
 NCLS: 548/135.000
 IC [7]
 ICM A61K031-433
 ICS C07D285-14
 IPCI A61K0031-433 [ICM,7]; C07D0285-14 [ICS,7]; C07D0285-00 [ICS,7,C*]
 IPCR C07D0285-00 [I,C*]; C07D0285-10 [I,A]; C07D0417-00 [I,C*];
 C07D0417-06 [I,A]; C07D0417-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 30 OF 61 USPATFULL on STN

Full Text

AN 2004:141077 USPATFULL
 TI Method of treating neurological diseases and etiologically related
 symptomology using carbonyl trapping agents in combination with
 medicaments
 IN Shapiro, Howard K., 214 Price Ave., Apt. F-32, Narberth, PA, United
 States 19072
 PI US 6746678 B1 20040608
 AI US 2000-545870 20000406 (9)
 RLI Continuation-in-part of Ser. No. US 1997-883290, filed on 26 Jun 1997,
 now abandoned Continuation-in-part of Ser. No. US 1993-62201, filed on
 29 Jun 1993, now patented, Pat. No. US 5668117, issued on 2 Aug 2000
 Continuation-in-part of Ser. No. US 1993-26617, filed on 23 Feb 1993,
 now abandoned Continuation of Ser. No. US 1991-660561, filed on 22 Feb
 1991, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 3419
 INCL INCLM: 424/400.000
 INCLS: 424/464.000; 424/451.000; 514/565.000; 514/561.000; 514/567.000
 NCL NCLM: 424/400.000
 NCLS: 424/451.000; 424/464.000; 514/561.000; 514/565.000; 514/567.000
 IC [7]
 ICM A61K009-00
 ICS A61K009-20; A61K006-48; A01N037-44
 IPCI A61K0009-00 [ICM,7]; A61K0009-20 [ICS,7]; A61K0006-48 [ICS,7];
 A01N0037-44 [ICS,7]
 IPCR A61K0031-18 [I,C*]; A61K0031-18 [I,A]; A61K0031-185 [I,C*];
 A61K0031-185 [I,A]; A61K0031-195 [I,A]; A61K0031-196 [I,A];
 A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-63 [I,C*];
 A61K0031-63 [I,A]; A61K0031-74 [I,C*]; A61K0031-785 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; G01N0033-68 [I,C*];
 G01N0033-68 [I,A]
 EXF 424/78.08; 424/464; 424/451; 424/400; 514/150; 514/565; 514/561; 514/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 31 OF 61 USPATFULL on STN

Full Text

AN 2004:113735 USPATFULL
 TI Compositions and methods for prophylactic and therapeutic
 supplementation of nutrition in subjects
 IN Giordano, John A., West Orange, NJ, UNITED STATES
 Balzer, Charles, Lavalette, NJ, UNITED STATES
 PI US 2004086574 A1 20040506
 US 6863904 B2 20050308
 AI US 2003-682927 A1 20031014 (10)
 RLI Continuation of Ser. No. US 2001-982205, filed on 19 Oct 2001, GRANTED,
 Pat. No. US 6660293
 PRAI US 2001-301443P 20010629 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1106
 INCL INCLM: 424/638.000
 INCLS: 424/655.000; 424/639.000; 424/643.000; 514/052.000; 514/251.000;
 514/168.000; 514/276.000; 514/356.000; 514/458.000; 514/474.000;
 424/702.000; 514/763.000; 514/440.000; 514/393.000
 NCL NCLM: 424/638.000
 NCLS: 424/630.000; 424/631.000; 424/632.000; 424/633.000; 424/634.000;
 424/635.000; 424/637.000; 424/639.000; 424/640.000; 424/641.000;
 424/643.000; 424/655.000; 424/682.000; 424/683.000; 424/686.000;
 424/688.000; 424/689.000; 424/692.000; 424/697.000; 424/702.000;
 514/052.000; 514/167.000; 514/168.000; 514/249.000; 514/251.000;
 514/276.000; 514/345.000; 514/355.000; 514/356.000; 514/387.000;
 514/440.000; 514/458.000; 514/474.000; 514/494.000; 514/499.000;
 514/500.000; 514/505.000; 514/563.000; 514/706.000; 514/725.000;
 514/729.000; 514/763.000; 514/824.000; 514/837.000; 514/838.000;
 514/866.000; 514/893.000; 514/894.000; 514/902.000; 514/904.000;
 514/905.000; 514/909.000; 514/910.000; 514/911.000; 514/925.000;
 514/393.000
 IC [7]
 ICM A61K033-32
 ICS A61K033-24; A61K033-04; A61K033-34; A61K031-714; A61K031-525;
 A61K031-51; A61K031-455

IPCI A61K0033-32 [ICM,7]; A61K0033-24 [ICS,7]; A61K0033-04 [ICS,7];
 A61K0033-34 [ICS,7]; A61K0031-714 [ICS,7]; A61K0031-7135
 [ICS,7,C*]; A61K0031-525 [ICS,7]; A61K0031-519 [ICS,7,C*];
 A61K0031-51 [ICS,7]; A61K0031-506 [ICS,7,C*]; A61K0031-455
 [ICS,7]
 IPCI-2 A61K0031-07 [ICM,7]; A61K0031-045 [ICM,7,C*]; A61K0031-28
 [ICS,7]; A61K0031-30 [ICS,7]; A61K0031-28 [ICS,7,C*];
 A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0031-375
 [ICS,7]; A61K0031-4415 [ICS,7]; A61K0031-51 [ICS,7]; A61K0031-506
 [ICS,7,C*]; A61K0031-525 [ICS,7]; A61K0031-519 [ICS,7,C*];
 A61K0031-714 [ICS,7]; A61K0031-7135 [ICS,7,C*]; A61K0033-24
 [ICS,7]
 IPCR A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-302 [I,C*];
 A23L0001-302 [I,A]; A23L0001-303 [I,A]; A23L0001-304 [I,C*];
 A23L0001-304 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];
 A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0033-00 [I,C*];
 A61K0033-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
 A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-26 [I,C*];
 A61K0047-26 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 32 OF 61 USPATFULL on STN

Full Text

AN 2004:82352 USPATFULL
 TI Maximizing effectiveness of substances used to improve health and well
 being
 IN Hermelin, Victor M., Chesterfield, MI, UNITED STATES
 PI US 2004062802 A1 20040401
 AI US 2003-644041 A1 20030820 (10)
 RLI Continuation of Ser. No. US 1999-475992, filed on 30 Dec 1999, PENDING
 Continuation-in-part of Ser. No. US 1999-323158, filed on 1 Jun 1999,
 GRANTED, Pat. No. US 6214379 Continuation of Ser. No. US 1998-53487,
 filed on 2 Apr 1998, GRANTED, Pat. No. US 5945123
 DT Utility
 FS APPLICATION
 LN.CNT 3143
 INCL INCLM: 424/468.000
 NCL NCLM: 424/468.000
 IC [7]
 ICM A61K009-22
 IPCI A61K0009-22 [ICM,7]
 IPCR A61K0009-22 [I,C*]; A61K0009-22 [I,A]; A61K0031-275 [I,C*];
 A61K0031-277 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4164 [I,A];
 A61K0031-4458 [I,C*]; A61K0031-4458 [I,A]; A61K0031-517 [I,C*];
 A61K0031-517 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A];
 A61K0031-551 [I,C*]; A61K0031-5513 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 33 OF 61 USPATFULL on STN

Full Text

AN 2004:18482 USPATFULL
 TI Additive method of standardized drinks and potable water production
 IN Costa, Fortunato, Linda-a-Velha, PORTUGAL
 PI US 2004013784 A1 20040122
 AI US 2003-239621 A1 20030127 (10)
 WO 2001-PT3 20010315
 PRAI PT 2000-102430 20000316
 DT Utility
 FS APPLICATION
 LN.CNT 1215
 INCL INCLM: 426/590.000
 NCL NCLM: 426/590.000
 IC [7]
 ICM C12C001-00
 IPCI C12C001-00 [ICM,7]
 IPCR A23L0001-29 [I,C*]; A23L0001-29 [I,A]; A23L0002-52 [I,C*];
 A23L0002-52 [I,A]; C02F0001-68 [I,C*]; C02F0001-68 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 34 OF 61 USPATFULL on STN

Full Text

AN 2003:325101 USPATFULL

TI Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
 IN Debnath, Bhuniya, Hyderabad, INDIA
 Das, Saibal Kumar, Hyderabad, INDIA
 Madhavan, Gurram Ranga, Hyderabad, INDIA
 Iqbal, Javed, Hyderabad, INDIA
 Chakrabarti, Ranjan, Hyderabad, INDIA
 Vikramadithyan, Reeba Kannimel, Hyderabad, INDIA
 PA DR. REDDY'S LABORATORIES LIMITED (non-U.S. corporation)
 PI US 2003229083 A1 20031211
 AI US 2002-306898 A1 20021127 (10)
 PRAI IN 2001-9712001 20011203
 DT Utility
 FS APPLICATION
 LN.CNT 3860
 INCL INCLM: 514/227.500
 INCLS: 514/228.200; 514/232.500; 514/235.500; 514/253.010; 514/253.060; 514/254.110; 514/314.000; 514/326.000; 514/357.000; 514/469.000; 544/060.000; 544/124.000; 544/128.000; 544/360.000; 544/375.000; 544/376.000; 544/363.000; 546/176.000; 546/196.000; 546/336.000; 549/460.000; 549/467.000
 NCL NCLM: 514/227.500
 NCLS: 514/228.200; 514/232.500; 514/235.500; 514/253.010; 514/253.060; 514/254.110; 514/314.000; 514/326.000; 514/357.000; 514/469.000; 544/060.000; 544/124.000; 544/128.000; 544/360.000; 544/363.000; 544/375.000; 544/376.000; 546/176.000; 546/196.000; 546/336.000; 549/460.000; 549/467.000
 IC [7]
 ICM A61K031-541
 ICS A61K031-5377; A61K031-496; A61K031-4709; A61K031-4439; A61K031-454; A61K031-353; C07D417-02; C07D413-02; C07D045-02; C07D043-02
 IPCI A61K0031-541 [ICM,7]; A61K0031-5377 [ICS,7]; A61K0031-5375 [ICS,7,C*]; A61K0031-496 [ICS,7]; A61K0031-4709 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-454 [ICS,7]; A61K0031-4523 [ICS,7,C*]; A61K0031-353 [ICS,7]; A61K0031-352 [ICS,7,C*]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]; C07D0413-02 [ICS,7]; C07D0413-00 [ICS,7,C*]; C07D0045-02 [ICS,7]; C07D0043-02 [ICS,7]
 IPCR A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C*]; A61K0031-454 [I,A]; A61K0031-4709 [I,C*]; A61K0031-4709 [I,A]; A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61K0031-541 [I,C*]; A61K0031-541 [I,A]; C07C0309-00 [I,C*]; C07C0309-73 [I,A]; C07C0311-00 [I,C*]; C07C0311-53 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 35 OF 61 USPATFULL on STN

Full Text

AN 2003:161965 USPATFULL
 TI Composition for treatment of stress
 IN Wurtman, Judith J., Boston, MA, United States
 Wurtman, Richard J., Boston, MA, United States
 PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
 PI US 6579899 B1 20030617
 AI US 2000-492110 20000127 (9)
 RLI Continuation-in-part of Ser. No. US 1999-354738, filed on 16 Jul 1999, now abandoned
 PRAI US 1998-93013P 19980716 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1055
 INCL INCLM: 514/419.000
 INCLS: 514/383.000; 514/252.150; 514/275.000; 514/221.000; 514/649.000
 NCL NCLM: 514/419.000
 NCLS: 514/221.000; 514/252.150; 514/275.000; 514/383.000; 514/649.000
 IC [7]
 ICM A61K031-405
 ICS A61K031-41; A61K031-497; A61K031-51; A61K031-137
 IPCI A61K0031-405 [ICM,7]; A61K0031-403 [ICM,7,C*]; A61K0031-41 [ICS,7]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*];

A61K0031-51 [ICS,7]; A61K0031-506 [ICS,7,C*]; A61K0031-137 [ICS,7]
 IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-135 [I,C*];
 A61K0031-135 [I,A]; A61K0031-138 [I,C*]; A61K0031-138 [I,A];
 A61K0031-15 [I,C*]; A61K0031-15 [I,A]; A61K0033-00 [I,C*];
 A61K0033-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
 EXF 424/330; 514/419; 514/383; 514/252.15; 514/275; 514/221; 514/649
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 36 OF 61 USPATFULL on STN

Full Text

AN 2003:146002 USPATFULL
 TI Thickened oil compositions of edible oil
 IN Eini, Meir, Nes Ziona, ISRAEL
 Tamarkin, Dov, Maccabim, ISRAEL
 PI US 2003099747 A1 20030529
 AI US 2002-169804 A1 20020709 (10)
 WO 2001-IL24 20010110
 PRAI IL 2000-133968 20000110
 IL 2000-133969 20000110
 IL 2000-137051 20000627
 IL 2000-137052 20000627
 DT Utility
 FS APPLICATION
 LN.CNT 3739
 INCL INCLM: 426/401.000
 NCL NCLM: 426/401.000
 IC [7]
 ICM A23B004-00
 IPCI A23B0004-00 [ICM,7]
 IPCR A21D0002-00 [I,C*]; A21D0002-14 [I,A]; A21D0002-16 [I,A];
 A23C0009-13 [I,C*]; A23C0009-13 [I,A]; A23C0011-00 [I,C*];
 A23C0011-04 [I,A]; A23C0013-00 [I,C*]; A23C0013-12 [I,A];
 A23C0015-00 [I,C*]; A23C0015-16 [I,A]; A23C0019-00 [I,C*];
 A23C0019-055 [I,A]; A23C0019-093 [I,A]; A23D0007-005 [I,C*];
 A23D0007-005 [I,A]; A23D0009-007 [I,C*]; A23D0009-007 [I,A];
 A23G0001-00 [I,C*]; A23G0001-00 [I,A]; A23G0003-34 [I,C*];
 A23G0003-34 [I,A]; A23J0003-00 [I,C*]; A23J0003-22 [I,A];
 A23L0001-00 [I,C*]; A23L0001-00 [I,A]; A23L0001-16 [I,C*];
 A23L0001-16 [I,A]; A23L0001-164 [I,C*]; A23L0001-164 [I,A];
 A23L0001-18 [I,C*]; A23L0001-18 [I,A]; A23L0001-214 [I,C*];
 A23L0001-217 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
 A23L0001-314 [I,C*]; A23L0001-314 [I,A]; A23L0001-39 [I,C*];
 A23L0001-40 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A];
 A61K0008-92 [I,C*]; A61K0008-92 [I,A]; A61K0009-00 [N,C*];
 A61K0009-00 [N,A]; A61K0031-351 [I,C*]; A61K0031-351 [I,A];
 A61K0031-65 [I,C*]; A61K0031-65 [I,A]; A61K0047-06 [I,C*];
 A61K0047-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A];
 A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0047-14 [N,C*];
 A61K0047-14 [N,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A];
 A61Q0019-00 [I,C*]; A61Q0019-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 37 OF 61 USPATFULL on STN

Full Text

AN 2003:113528 USPATFULL
 TI Biguanide and sulfonylurea formulations for the prevention and treatment
 of insulin resistance and type 2 diabetes mellitus
 IN Pearson, Don C., Lakewood, WA, UNITED STATES
 Richardson, Kenneth T., Anchorage, AK, UNITED STATES
 PA ChronoRX, LLC, Anchorage, AK, UNITED STATES (U.S. corporation)
 PI US 2003078269 A1 20030424
 US 6693094 B2 20040217
 AI US 2002-93476 A1 20020307 (10)
 PRAI US 2001-278270P 20010322 (60)
 US 2001-278271P 20010322 (60)
 US 2001-278296P 20010322 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4927
 INCL INCLM: 514/251.000
 INCLS: 514/553.000; 514/474.000; 514/561.000; 514/630.000

NCL NCLM: 514/188.000; 514/251.000
 NCLS: 514/255.060; 514/456.000; 514/458.000; 514/494.000; 514/505.000;
 514/565.000; 514/593.000; 514/635.000; 514/474.000; 514/553.000;
 514/561.000; 514/630.000

IC [7]
 ICM A61K031-525
 ICS A61K031-198; A61K031-185; A61K031-16; A61K031-375
 IPCI A61K0031-525 [ICM,7]; A61K0031-519 [ICM,7,C*]; A61K0031-198
 [ICS,7]; A61K0031-185 [ICS,7]; A61K0031-16 [ICS,7]; A61K0031-375
 [ICS,7]
 IPCI-2 A61K0031-555 [ICM,7]; A61K0031-4965 [ICS,7]; A61K0031-35 [ICS,7];
 A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0031-315
 [ICS,7]; A61K0031-28 [ICS,7]; A61K0031-195 [ICS,7]; A61K0031-185
 [ICS,7,C*]; A61K0031-175 [ICS,7]; A61K0031-17 [ICS,7,C*];
 A61K0031-155 [ICS,7]
 IPCR A61K0031-16 [I,C*]; A61K0031-16 [I,A]; A61K0031-185 [I,C*];
 A61K0031-185 [I,A]; A61K0031-198 [I,A]; A61K0031-375 [I,C*];
 A61K0031-375 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 38 OF 61 USPATFULL on STN

Full Text

AN 2003:99287 USPATFULL
 TI Ingestible nerve and circulatory nutritional formulation
 IN Harris, Dennis H., Scottsdale, AZ, UNITED STATES
 General, Ronald E., Scottsdale, AZ, UNITED STATES
 Martin, Robert, Scottsdale, AZ, UNITED STATES
 PI US 2003068391 A1 20030410
 AI US 2002-264589 A1 20021003 (10)
 PRAI US 2001-326784P 20011004 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 363
 INCL INCLM: 424/750.000
 INCLS: 424/769.000; 424/643.000; 514/440.000; 514/458.000; 514/474.000;
 514/725.000
 NCL NCLM: 424/750.000
 NCLS: 424/643.000; 424/769.000; 514/440.000; 514/458.000; 514/474.000;
 514/725.000

IC [7]
 ICM A61K035-78
 ICS A61K031-375; A61K031-385; A61K031-355; A61K033-32; A01N031-04;
 A61K031-07
 IPCI A61K0035-78 [ICM,7]; A61K0031-375 [ICS,7]; A61K0031-385 [ICS,7];
 A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0033-32
 [ICS,7]; A01N031-04 [ICS,7]; A01N031-00 [ICS,7,C*]; A61K0031-07
 [ICS,7]; A61K0031-045 [ICS,7,C*]
 IPCR A61K0031-352 [I,C*]; A61K0031-355 [I,A]; A61K0031-375 [I,C*];
 A61K0031-375 [I,A]; A61K0031-385 [I,C*]; A61K0031-385 [I,A];
 A61K0033-32 [I,C*]; A61K0033-32 [I,A]; A61K0045-00 [I,C*];
 A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 39 OF 61 USPATFULL on STN

Full Text

AN 2003:86901 USPATFULL
 TI Products containing highly unsaturated fatty acids for use by women and
 their children during stages of preconception, pregnancy and
 lactation/post-partum
 IN Elswyk, Mary Van, Longmont, CO, UNITED STATES
 PI US 2003060509 A1 20030327
 AI US 2002-228843 A1 20020826 (10)
 PRAI US 2001-314713P 20010824 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 909
 INCL INCLM: 514/560.000
 INCLS: 424/195.170
 NCL NCLM: 514/560.000
 NCLS: 424/195.170

IC [7]
 ICM A61K031-202

ICS A61K035-80
IPCI A61K0031-202 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0035-80
[ICS,7]
IPCR A61K0031-185 [I,C*]; A61K0031-202 [I,A]

L48 ANSWER 40 OF 61 USPATFULL on STN

Full Text

AN 2003:44448 USPATFULL
TI Nutritional frozen dessert and methods of manufacture
IN Koss, Ronald, Montpelier, VT, UNITED STATES
Koss, Arnold, South Burlington, VT, UNITED STATES
PI US 2003031758 A1 20030213
US 7169416 B2 20070130
AI US 2002-152429 A1 20020521 (10)
PRAI US 2001-292987P 20010523 (60)
US 2001-301566P 20010628 (60)
DT Utility
FS APPLICATION
LN.CNT 1861
INCL INCLM: 426/072.000
NCL NCLM: 426/072.000
NCLS: 426/074.000; 426/101.000; 426/524.000; 426/580.000; 426/583.000;
426/656.000; 426/658.000
IC [7]
ICM A23L001-30
IPCI A23L0001-30 [ICM,7]
IPCI-2 A23L0001-303 [I,A]; A23L0001-302 [I,C*]; A23L0001-304 [I,A]
IPCR A23G0009-04 [I,C*]; A23G0009-04 [I,A]; A23G0009-30 [I,A];
A23G0009-32 [I,C*]; A23G0009-32 [I,A]

L48 ANSWER 41 OF 61 USPATFULL on STN

Full Text

AN 2003:17975 USPATFULL
TI New monocyclic derivatives of aryl alkanolic acids and their use in
medicine: process for their preparation and pharmaceutical compositions
containing them
IN Iqbal, Javed, Hyderabad, INDIA
Madhavan, Gurram Ranga, Hyderabad, INDIA
Das, Saibal Kumar, Hyderabad, INDIA
Bhunia, Debnath, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
Rajagopalan, Ramanujam, Hyderabad, INDIA
PA DR. REDDY'S LABORATORIES LTD. (non-U.S. corporation)
PI US 2003013729 A1 20030116
AI US 2002-119300 A1 20020408 (10)
PRAI IN 2001-3012001 20010409
DT Utility
FS APPLICATION
LN.CNT 4579
INCL INCLM: 514/269.000
INCLS: 544/314.000
NCL NCLM: 514/269.000
NCLS: 544/314.000
IC [7]
ICM A61K031-513
ICS C07D239-36
IPCI A61K0031-513 [ICM,7]; C07D0239-36 [ICS,7]; C07D0239-00 [ICS,7,C*]
IPCR C07D0239-00 [I,C*]; C07D0239-36 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 42 OF 61 USPATFULL on STN

Full Text

AN 2003:17077 USPATFULL
TI Compositions and methods for prophylactic and therapeutic
supplementation of nutrition in subjects
IN Giordano, John A., West Orange, NJ, UNITED STATES
Balzer, Charles, Lavalette, NJ, UNITED STATES
PI US 2003012826 A1 20030116
US 6660293 B2 20031209
AI US 2001-982205 A1 20011019 (9)
PRAI US 2001-301443P 20010629 (60)
DT Utility

FS APPLICATION
LN.CNT 1107
INCL INCLM: 424/638.000
INCLS: 424/639.000; 424/643.000; 424/702.000; 424/682.000; 514/052.000;
514/168.000; 514/251.000; 514/355.000; 514/440.000; 514/393.000;
514/725.000; 514/563.000; 514/691.000; 514/763.000; 514/350.000;
514/458.000
NCL NCLM: 424/439.000; 424/638.000
NCLS: 424/400.000; 424/451.000; 424/464.000; 424/489.000; 424/639.000;
424/643.000; 424/682.000; 424/702.000; 514/052.000; 514/168.000;
514/251.000; 514/350.000; 514/355.000; 514/393.000; 514/440.000;
514/458.000; 514/563.000; 514/691.000; 514/725.000; 514/763.000
IC [7]
ICM A61K031-714
ICS A61K031-4415; A61K031-455; A61K031-525; A61K031-015; A61K031-07
IPCI A61K0031-714 [ICM,7]; A61K0031-7135 [ICM,7,C*]; A61K0031-4415
[ICS,7]; A61K0031-455 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519
[ICS,7,C*]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*];
A61K0031-07 [ICS,7]; A61K0031-045 [ICS,7,C*]
IPCI-2 A61K0047-00 [ICM,7]
IPCR A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-302 [I,C*];
A23L0001-302 [I,A]; A23L0001-303 [I,A]; A23L0001-304 [I,C*];
A23L0001-304 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];
A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0033-00 [I,C*];
A61K0033-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-26 [I,C*];
A61K0047-26 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 43 OF 61 USPATFULL on STN

Full Text

AN 2003:10267 USPATFULL
TI Orthomolecular vitamin E derivatives
IN Wilburn, Michael D., Cedar Hill, TX, UNITED STATES
PI US 2003007961 A1 20030109
AI US 2001-886472 A1 20010622 (9)
DT Utility
FS APPLICATION
LN.CNT 2622
INCL INCLM: 424/094.400
INCLS: 514/046.000; 514/054.000; 514/100.000; 514/052.000; 514/251.000;
514/336.000; 514/027.000; 514/458.000; 435/189.000; 536/008.000;
536/026.130; 536/027.300; 536/053.000; 544/257.000; 546/282.700;
549/406.000; 549/408.000
NCL NCLM: 424/094.400
NCLS: 435/189.000; 514/027.000; 514/046.000; 514/052.000; 514/054.000;
514/100.000; 514/251.000; 514/336.000; 514/458.000; 536/008.000;
536/026.130; 536/027.300; 536/053.000; 544/257.000; 546/282.700;
549/406.000; 549/408.000
IC [7]
ICM A61K038-44
ICS A61K031-726; A61K031-714
IPCI A61K0038-44 [ICM,7]; A61K0038-43 [ICM,7,C*]; A61K0031-726
[ICS,7]; A61K0031-714 [ICS,7]; A61K0031-7135 [ICS,7,C*]
IPCR C07D0311-00 [I,C*]; C07D0311-70 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 44 OF 61 USPATFULL on STN

Full Text

AN 2002:279731 USPATFULL
TI INTEGRATED MULTI-VITAMIN AND MINERAL COMBINATION
IN BENJAMIN, SAMUEL D., EAST SETAUKET, NY, UNITED STATES
WEIL, ANDREW, VAIL, AZ, UNITED STATES
PI US 2002155163 A1 20021024
AI US 1999-472669 A1 19991227 (9)
DT Utility
FS APPLICATION
LN.CNT 549
INCL INCLM: 424/600.000
INCLS: 424/617.000; 514/063.000; 514/064.000; 514/167.000; 514/168.000;
514/251.000; 514/276.000; 514/458.000; 514/440.000; 514/706.000
NCL NCLM: 424/600.000

NCLS: 424/617.000; 514/063.000; 514/064.000; 514/167.000; 514/168.000;
514/251.000; 514/276.000; 514/440.000; 514/458.000; 514/706.000

IC [7]
ICM A61K033-00
ICS A61K031-695; A61K031-69; A61K031-59; A61K031-525; A61K031-51;
A61K031-385; A61K031-355; A61K033-24; A61K031-095
IPCI A61K0033-00 [ICM,7]; A61K0031-695 [ICS,7]; A61K0031-69 [ICS,7];
A61K0031-59 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519
[ICS,7,C*]; A61K0031-51 [ICS,7]; A61K0031-506 [ICS,7,C*];
A61K0031-385 [ICS,7]; A61K0031-355 [ICS,7]; A61K0031-352
[ICS,7,C*]; A61K0033-24 [ICS,7]; A61K0031-095 [ICS,7]
IPCR A61K0031-045 [I,C*]; A61K0031-07 [I,A]; A61K0031-122 [I,C*];
A61K0031-122 [I,A]; A61K0031-14 [I,C*]; A61K0031-14 [I,A];
A61K0031-185 [I,C*]; A61K0031-196 [I,A]; A61K0031-197 [I,A];
A61K0031-352 [I,C*]; A61K0031-355 [I,A]; A61K0031-375 [I,C*];
A61K0031-375 [I,A]; A61K0031-385 [I,C*]; A61K0031-385 [I,A];
A61K0031-4164 [I,C*]; A61K0031-4188 [I,A]; A61K0031-4415 [I,C*];
A61K0031-4415 [I,A]; A61K0031-455 [I,C*]; A61K0031-455 [I,A];
A61K0031-506 [I,C*]; A61K0031-51 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; A61K0031-525 [I,A]; A61K0031-59 [I,C*];
A61K0031-59 [I,A]; A61K0031-7135 [I,C*]; A61K0031-714 [I,A];
A61K0033-00 [I,C*]; A61K0033-00 [I,A]; A61K0033-24 [I,C*];
A61K0033-24 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 45 OF 61 USPATFULL on STN

Full Text

AN 2002:265591 USPATFULL
TI Health promoting compositions
IN Clayton, Paul, London, UNITED KINGDOM
PI US 2002146463 A1 20021010
AI US 2001-14488 A1 20011214 (10)
PRAI DE 2001-10109798 20010301
EP 2000-127644 20001216
DT Utility
FS APPLICATION
LN.CNT 1453
INCL INCLM: 424/617.000
INCLS: 424/630.000; 424/643.000; 424/655.000; 514/003.000; 514/054.000;
514/393.000; 514/023.000; 514/458.000; 514/474.000; 514/725.000;
514/682.000; 514/763.000
NCL NCLM: 424/617.000
NCLS: 424/630.000; 424/643.000; 424/655.000; 514/003.000; 514/023.000;
514/054.000; 514/393.000; 514/458.000; 514/474.000; 514/682.000;
514/725.000; 514/763.000
IC [7]
ICM A61K038-28
ICS A61K031-015; A61K031-355; A61K033-34; A61K033-32
IPCI A61K0038-28 [ICM,7]; A61K0031-015 [ICS,7]; A61K0031-01
[ICS,7,C*]; A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*];
A61K0033-34 [ICS,7]; A61K0033-32 [ICS,7]
IPCR A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-302 [I,C*];
A23L0001-302 [I,A]; A23L0001-303 [I,A]; A23L0001-304 [I,C*];
A23L0001-304 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
A61K0031-01 [I,C*]; A61K0031-01 [I,A]; A61K0031-015 [I,A];
A61K0031-045 [I,C*]; A61K0031-047 [I,A]; A61K0031-07 [I,A];
A61K0031-122 [I,C*]; A61K0031-122 [I,A]; A61K0031-185 [I,C*];
A61K0031-197 [I,A]; A61K0031-202 [I,A]; A61K0031-205 [I,A];
A61K0031-352 [I,C*]; A61K0031-352 [I,A]; A61K0031-355 [I,A];
A61K0031-375 [I,C*]; A61K0031-375 [I,A]; A61K0031-4164 [I,C*];
A61K0031-4188 [I,A]; A61K0031-4415 [I,C*]; A61K0031-4415 [I,A];
A61K0031-455 [I,C*]; A61K0031-455 [I,A]; A61K0031-506 [I,C*];
A61K0031-51 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A];
A61K0031-525 [I,A]; A61K0031-59 [I,C*]; A61K0031-593 [I,A];
A61K0031-7008 [I,C*]; A61K0031-7008 [I,A]; A61K0031-702 [I,C*];
A61K0031-702 [I,A]; A61K0031-7135 [I,C*]; A61K0031-714 [I,A];
A61K0031-715 [I,C*]; A61K0031-715 [I,A]; A61K0031-716 [I,C*];
A61K0031-716 [I,A]; A61K0033-04 [I,C*]; A61K0033-04 [I,A];
A61K0033-06 [I,C*]; A61K0033-06 [I,A]; A61K0033-18 [I,C*];
A61K0033-18 [I,A]; A61K0033-24 [I,C*]; A61K0033-24 [I,A];
A61K0033-30 [I,C*]; A61K0033-30 [I,A]; A61K0033-32 [I,C*];
A61K0033-32 [I,A]; A61K0033-34 [I,C*]; A61K0033-34 [I,A];

A61K0036-00 [I,C*]; A61K0036-00 [I,A]; A61K0038-28 [I,C*];
 A61K0038-28 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0011-00 [I,C*];
 A61P0011-06 [I,A]; A61P0019-00 [I,C*]; A61P0019-02 [I,A];
 A61P0019-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-18 [I,A];
 A61P0025-22 [I,A]; A61P0027-00 [I,C*]; A61P0027-02 [I,A];
 A61P0039-00 [I,C*]; A61P0039-06 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 46 OF 61 USPATFULL on STN

Full Text

AN 2002:55067 USPATFULL
 TI Novel compounds having antiinflammatory activity: process for their
 preparation and pharmaceutical compositions containing them
 IN Pal, Manojit, Hyderabad, INDIA
 Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
 Ramanujam, Rajagopalan, Hyderabad, INDIA
 Misra, Parimal, Hyderabad, INDIA
 Mamnoor, Prem Kumar, Hyderabad, INDIA
 Casturi, Seshagiri Rao, Hyderabad, INDIA
 PA DR. REDDY'S LABORATORIES LTD. (non-U.S. corporation)
 PI US 2002032230 A1 20020314
 US 6686390 B2 20040203
 AI US 2001-861903 A1 20010521 (9)
 PRAI IN 2000-3882000 20000522
 DT Utility
 FS APPLICATION
 LN.CNT 3203
 INCL INCLM: 514/473.000
 INCLS: 549/295.000; 549/299.000
 NCL NCLM: 514/473.000
 NCLS: 514/231.500; 514/443.000; 544/152.000; 549/053.000; 549/295.000;
 549/299.000
 IC [7]
 ICM A61K031-365
 ICS C07D037-20
 IPCI A61K0031-365 [ICM,7]; C07D0037-20 [ICS,7]
 IPCI-2 A61K0031-34 [ICM,7]; A61K0031-38 [ICS,7]
 IPCR C07D0207-00 [I,C*]; C07D0207-38 [I,A]; C07D0207-444 [I,A];
 C07D0307-00 [I,C*]; C07D0307-58 [I,A]; C07D0307-60 [I,A];
 C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0417-00 [I,C*];
 C07D0417-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 47 OF 61 USPATFULL on STN

Full Text

AN 2000:105939 USPATFULL
 TI Ocular orally ingested composition for prevention and treatment of
 individuals
 IN Gorsek, Wayne F., Springfield, IL, United States
 PA VitaCost Inc., Springfield, IL, United States (U.S. corporation)
 PI US 6103756 20000815
 AI US 1999-372055 19990811 (9)
 DT Utility
 FS Granted
 LN.CNT 133
 INCL INCLM: 514/458.000
 INCLS: 514/474.000; 514/725.000; 514/912.000; 514/913.000
 NCL NCLM: 514/458.000
 NCLS: 514/474.000; 514/725.000; 514/912.000; 514/913.000
 IC [7]
 ICM A61K031-355
 ICS A61K031-07
 IPCI A61K0031-355 [ICM,7]; A61K0031-352 [ICM,7,C*]; A61K0031-07
 [ICS,7]; A61K0031-045 [ICS,7,C*]
 IPCR A61K0045-00 [I,C*]; A61K0045-06 [I,A]
 EXF 514/458; 514/474; 514/725; 514/912; 514/913

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 48 OF 61 USPATFULL on STN

Full Text

AN 1999:146556 USPATFULL
TI Advanced glycation end-product intermediaries and post-amadori inhibition
IN Hudson, Billy G., Omaha Park, AR, United States
Todd, Parvin, Kansas City, KS, United States
Khalifah, Raja Gabriel, Overland Park, KS, United States
Booth, Aaron Ashley, Kansas City, KS, United States
PA Kansas University Medical Center, Kansas City, KS, United States (U.S. corporation)
PI US 5985857 19991116
AI US 1996-711555 19960910 (8)
PRAI US 1995-3628P 19950912 (60)
DT Utility
FS Granted
LN.CNT 1804
INCL INCLM: 514/089.000
INCLS: 514/345.000; 514/351.000; 514/247.000; 514/256.000; 514/276.000; 514/023.000; 514/025.000
NCL NCLM: 514/089.000
NCLS: 514/023.000; 514/025.000; 514/247.000; 514/256.000; 514/276.000; 514/345.000; 514/351.000
IC [6]
ICM A61K031-00
IPCI A61K0031-00 [ICM,6]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-04 [I,C*]; A61K0031-04 [I,A]; A61K0031-435 [I,C*]; A61K0031-435 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4415 [I,C*]; A61K0031-4415 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-675 [I,C*]; A61K0031-675 [I,A]; A61K0038-05 [I,C*]; A61K0038-05 [I,A]; A61K0038-06 [I,C*]; A61K0038-06 [I,A]; A61K0038-07 [I,C*]; A61K0038-07 [I,A]; C07K0005-00 [I,C*]; C07K0005-06 [I,A]; C07K0005-087 [I,A]; G01N0033-68 [I,C*]; G01N0033-68 [I,A]
EXF 514/2; 514/89; 514/345; 514/351; 514/247; 514/256; 514/276; 514/23; 514/25

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 49 OF 61 USPATFULL on STN

Full Text

AN 1999:146039 USPATFULL
TI Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products
IN Kamarei, A. Reza, 176 Loomis Ct., Princeton, NJ, United States 08540
PI US 5985339 19991116
AI US 1997-975692 19971121 (8)
PRAI US 1996-31637P 19961122 (60)
DT Utility
FS Granted
LN.CNT 1930
INCL INCLM: 426/072.000
INCLS: 426/073.000; 426/074.000; 426/397.000; 426/410.000; 426/541.000; 426/590.000; 426/648.000; 426/656.000; 426/658.000; 229/125.420; 229/249.000; 514/002.000; 514/021.000
NCL NCLM: 426/072.000
NCLS: 229/125.420; 229/249.000; 426/073.000; 426/074.000; 426/397.000; 426/410.000; 426/541.000; 426/590.000; 426/648.000; 426/656.000; 426/658.000; 514/002.000; 514/021.000
IC [6]
ICM A23L001-30
IPCI A23L0001-30 [ICM,6]
IPCR A23C0009-00 [I,C*]; A23C0009-152 [I,C*]; A23C0009-152 [I,A]; A23C0009-158 [I,A]; A23C0009-20 [I,A]; A23L0001-29 [I,C*]; A23L0001-29 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-302 [I,C*]; A23L0001-302 [I,A]; A23L0001-303 [I,A]; A23L0001-304 [I,C*]; A23L0001-304 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A23L0002-42 [I,C*]; A23L0002-46 [I,A]; A23L0002-52 [I,C*]; A23L0002-66 [I,A]
EXF 426/72; 426/73; 426/74; 426/590; 426/541; 426/658; 426/648; 426/656; 426/397; 426/410; 229/249; 229/125.42; 514/21; 514/2

L48 ANSWER 50 OF 61 USPATFULL on STN

Full Text

AN 1999:137222 USPATFULL
 TI Nutrient composition for treatment of immune disorders
 IN Khaled, F. Mahnaz, Pelham, AL, United States
 PA Life Sciences' Technologies, Inc., Birmingham, AL, United States (U.S. corporation)
 PI US 5977073 19991102
 AI US 1991-711530 19910606 (7)
 DT Utility
 FS Granted
 LN.CNT 429
 INCL INCLM: 514/019.000
 INCLS: 530/331.000; 546/301.000; 549/315.000; 549/408.000; 585/351.000; 562/553.000
 NCL NCLM: 514/019.000
 NCLS: 530/331.000; 546/301.000; 549/315.000; 549/408.000; 562/553.000; 585/351.000
 IC [6]
 ICM A61K038-00
 IPCI A61K0038-00 [ICM,6]
 IPCR A61K0038-04 [I,C*]; A61K0038-04 [I,A]; A61K0038-06 [I,C*]; A61K0038-06 [I,A]
 EXF 530/331; 514/19; 546/301; 549/408; 549/315; 585/351; 562/553
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 51 OF 61 USPATFULL on STN

Full Text

AN 1999:37091 USPATFULL
 TI Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
 IN Sandyk, Reuven, 7 Piper Ct., Roslyn, NY, United States 11576
 PI US 5885976 19990323
 AI US 1997-978383 19971125 (8)
 RLI Continuation-in-part of Ser. No. US 1995-437273, filed on 8 May 1995, now patented, Pat. No. US 5691324
 DT Utility
 FS Granted
 LN.CNT 1969
 INCL INCLM: 519/159.000
 INCLS: 514/160.000; 514/250.000; 514/345.000; 514/355.000; 514/419.000; 514/654.000; 514/657.000
 NCL NCLM: 514/159.000
 NCLS: 514/160.000; 514/250.000; 514/345.000; 514/355.000; 514/419.000; 514/654.000; 514/657.000
 IC [6]
 ICM A61K031-60
 IPCI A61K0031-60 [ICM,6]
 IPCR A61N0002-00 [I,C*]; A61N0002-00 [I,A]
 EXF 514/159; 514/160; 514/250; 514/355; 514/345; 514/419; 514/654; 514/657
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 52 OF 61 USPATFULL on STN

Full Text

AN 97:83944 USPATFULL
 TI Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
 IN Shapiro, Howard K., 214 Price Ave. F32, Narberth, PA, United States 19072
 PI US 5668117 19970916
 AI US 1993-62201 19930629 (8)
 RLI Continuation-in-part of Ser. No. US 1993-26617, filed on 23 Feb 1993, now abandoned which is a continuation of Ser. No. US 1991-660561, filed on 22 Feb 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3963
 INCL INCLM: 514/055.000
 INCLS: 514/054.000; 514/023.000; 514/001.000; 514/811.000; 514/866.000; 514/878.000; 514/879.000; 514/903.000; 514/912.000; 436/518.000; 436/074.000; 536/001.110; 536/020.000
 NCL NCLM: 514/055.000

NCLS: 436/074.000; 436/518.000; 514/001.000; 514/023.000; 514/054.000;
514/811.000; 514/866.000; 514/878.000; 514/879.000; 514/903.000;
514/912.000; 536/001.110; 536/020.000

IC [6]
ICM A01N043-04
ICS A01N061-00; C07H001-00; C08B037-08
IPCI A01N0043-04 [ICM,6]; A01N0043-02 [ICM,6,C*]; A01N0061-00 [ICS,6];
C07H0001-00 [ICS,6]; C08B0037-08 [ICS,6]; C08B0037-00 [ICS,6,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-195 [I,A]; A61K0031-196 [I,A];
G01N0033-68 [I,C*]; G01N0033-68 [I,A]
EXF 514/55; 514/54; 514/23; 514/1; 514/811; 514/866; 514/878; 514/879;
514/903; 514/912; 435/6; 435/7.9; 436/518; 436/74; 436/87; 536/1.11;
536/20

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 53 OF 61 USPATFULL on STN

Full Text

AN 97:10057 USPATFULL
TI Use of DL-lipoic acid as a medical food in the treatment of diabetes
mellitus
IN Fischer, Frederick B., 6685 Phillips Mill Rd., Box 6, Solebury, PA,
United States 18963
PI US 5599835 19970204
AI US 1994-344131 19941123 (8)
DT Utility
FS Granted
LN.CNT 339
INCL INCLM: 514/440.000
NCL NCLM: 514/440.000
IC [6]
ICM A01N043-26
IPCI A01N0043-26 [ICM,6]; A01N0043-02 [ICM,6,C*]
IPCR A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A61K0031-506 [I,C*];
A61K0031-51 [I,A]

EXF 514/440

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 54 OF 61 USPATFULL on STN

Full Text

AN 96:48178 USPATFULL
TI Pharmaceutical compositions for the treatment of diabetic male sexual
dysfunction
IN Shlyankevich, Mark, Watterbury, CT, United States
PA Bio-Virus Research Incorporated, San Mateo, CA, United States (U.S.
corporation)
PI US 5523087 19960604
AI US 1995-389006 19950215 (8)
DT Utility
FS Granted
LN.CNT 204
INCL INCLM: 424/195.100
INCLS: 514/182.000; 514/456.000
NCL NCLM: 424/757.000
NCLS: 424/725.000; 424/774.000; 514/182.000; 514/456.000
IC [6]
ICM A61K035-78
ICS A61K031-56; A61K031-35
IPCI A61K0035-78 [ICM,6]; A61K0031-56 [ICS,6]; A61K0031-35 [ICS,6]
IPCR A61K0031-35 [I,C*]; A61K0031-35 [I,A]; A61K0031-56 [I,C*];
A61K0031-56 [I,A]

EXF 514/456; 514/182; 424/195.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 55 OF 61 USPATFULL on STN

Full Text

AN 91:75692 USPATFULL
TI Insulin derivatives, a process for their preparation, and their use
IN Lobermann, Hartmut, Weimar, Germany, Federal Republic of
Paques, Eric P., Marburg, Germany, Federal Republic of
Heimbürger, Norbert, Marburg, Germany, Federal Republic of
PA Behringwerke Aktiengesellschaft, Marburg/Lahn, Germany, Federal Republic
of (non-U.S. corporation)

PI US 5049545 19910917
 AI US 1989-323156 19890315 (7)
 RLI Continuation of Ser. No. US 1987-14462, filed on 13 Feb 1987, now abandoned
 PRAI DE 1986-3604868 19860215
 DT Utility
 FS Granted
 LN.CNT 392
 INCL INCLM: 514/003.000
 INCLS: 514/004.000; 530/303.000; 530/305.000
 NCL NCLM: 514/003.000
 NCLS: 514/004.000; 530/303.000; 530/305.000
 IC [5]
 ICM A61K037-26
 ICS C07K007-40
 IPCI A61K0037-26 [ICM,5]; C07K0007-40 [ICS,5]
 IPCR C07K0014-575 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A];
 A61K0038-28 [I,C*]; A61K0038-28 [I,A]; A61P0003-00 [I,C*];
 A61P0003-08 [I,A]; C07K0001-00 [I,C*]; C07K0001-06 [I,A];
 C07K0001-113 [I,A]; C07K0014-435 [I,C*]; C07K0014-62 [I,A];
 C07K0014-76 [I,A]; C07K0014-81 [I,C*]; C07K0014-81 [I,A];
 C07K0019-00 [I,C*]; C07K0019-00 [I,A]
 EXF 530/303-305; 514/3-4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 56 OF 61 USPATFULL on STN

Full Text

AN 85:72405 USPATFULL
 TI Treatment of metabolic disorders with dichloroacetate-thiamine preparations
 IN Stacpoole, Peter W., Gainesville, FL, United States
 PA University of Florida, Gainesville, FL, United States (U.S. corporation)
 PI US 4558050 19851210
 AI US 1984-584994 19840301 (6)
 DT Utility
 FS Granted
 LN.CNT 313
 INCL INCLM: 514/252.000
 INCLS: 544/327.000
 NCL NCLM: 514/276.000
 NCLS: 544/327.000
 IC [4]
 ICM A61K031-505
 ICS C07D239-02; C07D415-00
 IPCI A61K0031-505 [ICM,4]; C07D0239-02 [ICS,4]; C07D0239-00 [ICS,4,C*]; C07D0415-00 [ICS,4]
 IPCR C07D0415-00 [I,C*]; C07D0415-00 [I,A]
 EXF 544/327; 424/251; 514/252
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 57 OF 61 USPATFULL on STN

Full Text

AN 81:70744 USPATFULL
 TI Accelerating cellular repair composition for the human body and method of administering same
 IN Caspe, Saul, 54 W. 16th St., New York, NY, United States 10011
 PI US 4308257 19811229
 AI US 1980-156190 19800603 (6)
 DT Utility
 FS Granted
 LN.CNT 358
 INCL INCLM: 424/180.000
 INCLS: 424/177.000
 NCL NCLM: 424/094.200
 NCLS: 514/047.000
 IC [3]
 ICM A61K031-44
 ICS A61K031-465
 IPCI A61K0031-44 [ICM,3]; A61K0031-465 [ICS,3]
 IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-28 [I,C*];
 A61K0009-28 [I,A]
 EXF 424/180; 424/177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 58 OF 61 USPAT2 on STN

Full Text

AN 2004:320669 USPAT2
TI Inhibitors of apoptosis of nerve cells
IN Basic, Robert, Dubravica 30, Zagreb, CROATIA 10000
Slijepcevic, Milivoj, Zmajevac 10, Zagreb, CROATIA 10000
Hadzija, Mirko, G. Tadino 18, Zagreb, CROATIA 10000
Hadzija, Marijana, G. Tadino 18, Zagreb, CROATIA 10000
PI US 6953595 B2 20051011
WO 2001095920 20011220
AI US 2002-311392 20010504 (10)
WO 2001-HR19 20010504
20021213 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 776
INCL INCLM: 424/725.000
INCLS: 424/773.000; 424/774.000; 514/770.000
NCL NCLM: 424/725.000; 424/684.000
NCLS: 424/773.000; 424/774.000; 514/770.000; 424/757.000; 514/052.000;
514/251.000; 514/276.000; 514/350.000; 514/356.000
IC [7]
ICM A61K035-78
IPCI A61K0035-78 [ICM,7]; A61K0033-06 [ICS,7]; A61K0031-525 [ICS,7];
A61K0031-519 [ICS,7,C*]; A61K0031-51 [ICS,7]; A61K0031-506
[ICS,7,C*]
IPCI-2 A61K0035-78 [ICM,7]
IPCR A61K0031-506 [I,C*]; A61K0031-51 [I,A]; A61K0031-519 [I,C*];
A61K0031-525 [I,A]; A61K0033-06 [I,C*]; A61K0033-06 [I,A];
A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0003-00 [I,C*];
A61P0003-10 [I,A]; A61P0025-00 [I,C*]; A61P0025-02 [I,A]
EXF 424/725; 424/773; 424/774; 514/770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 59 OF 61 USPAT2 on STN

Full Text

AN 2003:113528 USPAT2
TI Biguanide and sulfonylurea formulations for the prevention and treatment
of insulin resistance and type 2 diabetes mellitus
IN Pearson, Don C., Lakewood, WA, United States
Richardson, Kenneth T., Anchorage, AK, United States
PA Chrono RX LLC, Anchorage, AK, United States (U.S. corporation)
PI US 6693094 B2 20040217
AI US 2002-93476 20020307 (10)
PRAI US 2001-278296P 20010322 (60)
US 2001-278270P 20010322 (60)
US 2001-278271P 20010322 (60)
DT Utility
FS GRANTED
LN.CNT 4817
INCL INCLM: 514/188.000
INCLS: 514/255.060; 514/456.000; 514/458.000; 514/494.000; 514/505.000;
514/565.000; 514/593.000; 514/635.000
NCL NCLM: 514/188.000; 514/251.000
NCLS: 514/255.060; 514/456.000; 514/458.000; 514/494.000; 514/505.000;
514/565.000; 514/593.000; 514/635.000; 514/474.000; 514/553.000;
514/561.000; 514/630.000
IC [7]
ICM A61K031-555
ICS A61K031-4965; A61K031-35; A61K031-355; A61K031-315; A61K031-28;
A61K031-195; A61K031-175; A61K031-155
IPCI A61K0031-525 [ICM,7]; A61K0031-519 [ICM,7,C*]; A61K0031-198
[ICS,7]; A61K0031-185 [ICS,7]; A61K0031-16 [ICS,7]; A61K0031-375
[ICS,7]
IPCI-2 A61K0031-555 [ICM,7]; A61K0031-4965 [ICS,7]; A61K0031-35 [ICS,7];
A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0031-315
[ICS,7]; A61K0031-28 [ICS,7]; A61K0031-195 [ICS,7]; A61K0031-185
[ICS,7,C*]; A61K0031-175 [ICS,7]; A61K0031-17 [ICS,7,C*];
A61K0031-155 [ICS,7]
IPCR A61K0031-16 [I,C*]; A61K0031-16 [I,A]; A61K0031-185 [I,C*];

A61K0031-185 [I,A]; A61K0031-198 [I,A]; A61K0031-375 [I,C*];
A61K0031-375 [I,A]; A61K0031-519 [I,C*]; A61K0031-525 [I,A]
EXF 514/188; 514/255.06; 514/456; 514/458; 514/494; 514/505; 514/565;
514/593; 514/635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 60 OF 61 USPAT2 on STN

Full Text

AN 2003:17077 USPAT2
TI Compositions and methods for prophylactic and therapeutic
supplementation of nutrition in subjects
IN Giordano, John A., West Orange, NJ, United States
Balzer, Charles, Lavalette, NJ, United States
PA Everett Laboratories, Inc., West Orange, NJ, United States (U.S.
corporation)
PI US 6660293 B2 20031209
AI US 2001-982205 20011019 (9)
PRAI US 2001-301443P 20010629 (60)
DT Utility
FS GRANTED
LN.CNT 1034
INCL INCLM: 424/439.000
INCLS: 424/400.000; 424/451.000; 424/464.000; 424/489.000
NCL NCLM: 424/439.000; 424/638.000
NCLS: 424/400.000; 424/451.000; 424/464.000; 424/489.000; 424/639.000;
424/643.000; 424/682.000; 424/702.000; 514/052.000; 514/168.000;
514/251.000; 514/350.000; 514/355.000; 514/393.000; 514/440.000;
514/458.000; 514/563.000; 514/691.000; 514/725.000; 514/763.000
IC [7]
ICM A61K047-00
IPCI A61K0031-714 [ICM,7]; A61K0031-7135 [ICM,7,C*]; A61K0031-4415
[ICS,7]; A61K0031-455 [ICS,7]; A61K0031-525 [ICS,7]; A61K0031-519
[ICS,7,C*]; A61K0031-015 [ICS,7]; A61K0031-01 [ICS,7,C*];
A61K0031-07 [ICS,7]; A61K0031-045 [ICS,7,C*]
IPCI-2 A61K0047-00 [ICM,7]
IPCR A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-302 [I,C*];
A23L0001-302 [I,A]; A23L0001-303 [I,A]; A23L0001-304 [I,C*];
A23L0001-304 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A];
A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0033-00 [I,C*];
A61K0033-00 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-26 [I,C*];
A61K0047-26 [I,A]
EXF 424/400; 424/439; 424/451; 424/464; 424/489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 61 OF 61 USPAT2 on STN

Full Text

AN 2002:55067 USPAT2
TI Compounds having antiinflammatory activity: process for their preparation
and pharmaceutical compositions containing them
IN Pal, Manojit, Hyderabad, INDIA
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Ramanujam, Rajagopalan, Hyderabad, INDIA
Misra, Parimal, Hyderabad, INDIA
Mamnoor, Prem Kumar, Hyderabad, INDIA
Casturi, Seshagiri Rao, Hyderabad, INDIA
PA Dr. Reddy's Laboratories Limited, Hyderabad, INDIA (non-U.S.
corporation)
PI US 6686390 B2 20040203
AI US 2001-861903 20010521 (9)
PRAI IN 2000-3882000 20000522
IN 2000-4362000 20000608
DT Utility
FS GRANTED
LN.CNT 2891
INCL INCLM: 514/473.000
INCLS: 514/231.500; 514/443.000; 549/053.000; 549/295.000; 544/152.000
NCL NCLM: 514/473.000
NCLS: 514/231.500; 514/443.000; 544/152.000; 549/053.000; 549/295.000;
549/299.000
IC [7]
ICM A61K031-34

```

ICS      A61K031-38
IPCI     A61K0031-365 [ICM,7]; C07D0037-20 [ICS,7]
IPCI-2   A61K0031-34 [ICM,7]; A61K0031-38 [ICS,7]
IPCR     C07D0207-00 [I,C*]; C07D0207-38 [I,A]; C07D0207-444 [I,A];
          C07D0307-00 [I,C*]; C07D0307-58 [I,A]; C07D0307-60 [I,A];
          C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0417-00 [I,C*];
          C07D0417-10 [I,A]
EXF      514/473; 514/231.5; 514/443; 549/295; 549/53; 544/152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

```

=> s (pioglitazone or rosiglitazone or cs-011)
L49      4319 (PIOGLITAZONE OR ROSIGLITAZONE OR CS-011)

```

=> d his

(FILE 'HOME' ENTERED AT 19:09:39 ON 08 JUN 2007)

FILE 'REGISTRY' ENTERED AT 19:09:50 ON 08 JUN 2007

```

          E VITAMIN B1/CN
L1        1 S E3
          E PIOGLITAZONE/CN
L2        1 S E3
          E ROSIGLITAZONE/CN
L3        1 S E3
          E CS-011/CN
          E CS 011/CN
L4        1 S E3
          E TAK 559/CN
L5        1 S E3
          E FK 614/CN
L6        1 S E3

```

FILE 'MRCK' ENTERED AT 19:18:15 ON 08 JUN 2007

```

L7        1 S L1
L8        1 S L2
L9        1 S L3
L10       0 S L4
L11       0 S L5
L12       0 S L6

```

FILE 'MEDLINE' ENTERED AT 19:20:32 ON 08 JUN 2007

```

L13       7457 S L1
L14       12991 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L15       13000 S L13 OR L14
L16       1041 S L2
L17       1426 S PIOGLITAZONE
L18       1426 S L16 OR L17
L19       1361 S L3
L20       1891 S ROSIGLITAZONE
L21       1891 S L19 OR L20
L22       0 S CS-011
L23       5 S (TAK-559 OR FK-614)
L24       0 S L15 AND L18
L25       0 S L14 AND L21
L26       0 S L14 AND L23
L27       286036 S DIABET?
L28       0 S L15 AND L21
L29       317 S L15 AND L27

```

FILE 'CA' ENTERED AT 19:24:59 ON 08 JUN 2007

```

L30       1975 S L3
L31       9 S L4
L32       19 S L5
L33       23 S L6
L34       23452 S L1
L35       1 S L31 AND L34
L36       1 S L32 AND L34
L37       1 S L33 AND L34
L38       133460 S DIABET?/AB,BI
L39       355 S L34 AND L38

```

FILE 'USPATFULL, USPAT2' ENTERED AT 19:30:17 ON 08 JUN 2007

E KAWASUGI K/IN

L40 1 S E4
L41 1017 S L1
L42 14147 S (VITAMIN B1 OR THIAMINE OR THIAMIN)
L43 81684 S DIABET?
L44 14292 S L41 OR L42
L45 2842 S L43 AND L44
L46 1132 S (VITAMIN B1 OR THIAMINE OR THIAMIN)/CLM
L47 15924 S DIABET?/CLM
L48 61 S L46 AND L47
L49 4319 S (PIOGLITAZONE OR ROSIGLITAZONE OR CS-011)

=> s 142 and 149

L50 327 L42 AND L49

=> s (pioglitazone or rosiglitazone or cs-011)/clm

L51 669 (PIOGLITAZONE OR ROSIGLITAZONE OR CS-011)/CLM

=> s 146 and 151

L52 3 L46 AND L51

=> d 1-3

L52 ANSWER 1 OF 3 USPATFULL on STN

Full Text

AN 2007:134049 USPATFULL
TI Lyophilization process and products obtained thereby
IN Palepu, Nageswara R., Mill Creek, WA, UNITED STATES
PI US 2007116729 A1 20070524
AI US 2005-282507 A1 20051118 (11)
DT Utility
FS APPLICATION
LN.CNT 3917
INCL INCLM: 424/400.000
INCLS: 034/287.000; 514/035.000; 514/263.340; 514/291.000; 514/192.000;
514/200.000; 514/282.000; 514/254.070; 514/304.000; 514/649.000
NCL NCLM: 424/400.000
NCLS: 034/287.000; 514/035.000; 514/263.340; 514/291.000; 514/192.000;
514/200.000; 514/282.000; 514/254.070; 514/304.000; 514/649.000
IC IPCI A61K0009-00 [I,A]; F26B0005-06 [I,A]; F26B0005-04 [I,C*]

L52 ANSWER 2 OF 3 USPATFULL on STN

Full Text

AN 2006:333434 USPATFULL
TI Skin care compositions
IN Haber, C. Andrew, Toronto, CANADA
PI US 2006286046 A1 20061221
AI US 2005-28616 A1 20050105 (11)
DT Utility
FS APPLICATION
LN.CNT 1439
INCL INCLM: 424/059.000
INCLS: 424/401.000; 514/554.000; 514/562.000; 514/548.000; 514/263.310
NCL NCLM: 424/059.000
NCLS: 424/401.000; 514/263.310; 514/548.000; 514/554.000; 514/562.000
IC IPCI A61K0008-49 [I,A]; A61K0008-30 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 3 OF 3 USPATFULL on STN

Full Text

AN 2004:320661 USPATFULL
TI Melt extrusion of salts of active ingredients
IN Petereit, Hans-Ulrich, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Meier, Christian, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Gryczke, Andreas, Buettelborn, GERMANY, FEDERAL REPUBLIC OF
PI US 2004253314 A1 20041216
AI US 2004-498829 A1 20040624 (10)
WO 2003-EP935 20030130
PRAI DE 2002-10208344 20020227
DT Utility
FS APPLICATION

LN.CNT 827
 INCL INCLM: 424/487.000
 INCLS: 264/109.000
 NCL NCLM: 424/487.000
 NCLS: 264/109.000
 IC [7]
 ICM A61K009-14
 ICS D04H001-00; B27N003-00
 IPCI A61K0009-14 [ICM,7]; D04H0001-00 [ICS,7]; B27N0003-00 [ICS,7]
 IPCR A61K0047-32 [I,C*]; A61K0047-32 [I,A]; A61K0009-16 [I,C*];
 A61K0009-16 [I,A]; A61K0009-20 [I,C*]; A61K0009-20 [I,A];
 C08K0005-00 [I,C*]; C08K0005-00 [I,A]; C08L0033-00 [I,C*];
 C08L0033-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 2

L52 ANSWER 2 OF 3 USPATFULL on STN

CLM What is claimed is:

7. A skin care composition as claimed in claim 1 wherein said reactive carbonyl scavenger is aminoguanidine, dimethylbiguanide (metformin), [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-]thiazolidine-dione (**pioglitazone**), 3,7-Dihydro-3,7dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione (pentoxifylline), D-penicillamine, **thiamine** pyrophosphate, pyridoxamine, 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid (diclofenac), inositol, N-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate (benfotiamine), (+)-3-(2-thienyl)-2-piperazine (Tenilsetam), 3,4,5-trihydroxystilbene (resveratrol), (±)-2-isopropylidenhydrazono-4-oxo-thiazolidin-5-ylacetalinide (OPB-9195), diaminophenazine, LR-9,4-(2-naphtylcarboxamido)phenoxyisobutyric acid, LR-20, . . .

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
82.68	214.25

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 19:37:22 ON 08 JUN 2007